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Influenza is a respiratory pathogen that, despite the availability of vaccines, continues to 
have an enormous impact on human health and world economy. In addition to seasonal 
epidemics, the persistent threat posed by newly emergent pathogenic strains highlights the 
need to better understand mechanisms that underlie protective and pathogenic host responses. 
To address this issue, we used a multi-pronged approach. First, we sought to examine humoral 
and cellular immunity against seasonal and novel influenza viruses using a human vaccine 
cohort established during the 2006-07 and the 2007-08 influenza seasons. The vast majority of 
past studies have focused on strain-specific serum antibodies as the sole correlate of protection 
against influenza. However, we show that in addition to antibody responses, seasonal trivalent 
inactivated (TIV) and live attenuated (LAIV) influenza vaccines also induced significant 
increases in influenza-specific T cells post vaccination. Importantly, unlike antibodies, T cells 
established by seasonal vaccination and/or infection were highly cross-reactive against novel 
influenza viruses, namely the pandemic 2009 H1N1 virus. In addition, we also detected 
significant and sustained changes in serum cytokine profiles after vaccination with TIV but not 
LAIV suggesting that the different vaccines may activate different immunological compartments. 
Future studies examining mucosal immune responses may provide more insight into 
immunological mechanisms underlying protective immunity following LAIV. In the second part of 
this thesis, we examined the role of the potent anti-inflammatory cytokine IL-10 in the 
pathogenesis of lethal influenza infections using a mouse model. IL-10 deficiency was, 
somewhat counterintuitively, associated with significantly lower morbidity and mortality 
suggesting that expression of IL-10 was pathogenic during lethal influenza infections. IL-10 
expression in WT animals was associated with higher pulmonary damage and compromised 
pulmonary function compared to Il10-/-animals. Interestingly, IL-10 negatively regulated the 
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expression of IL-22, a cytokine that has recently emerged as an important mediator of tissue 
homeostasis, particularly in the mucosa. However, improved disease outcomes in Il10-/- was 
independent of IL-22 as genetic ablation of IL-22 in Il10-/- mice (ie. Il10-/-Il22-/-) had no impact on 
survival rates. Finally, using a less virulent strain of influenza, namely A/WSN/33, we show that 
the pathogenic effects of IL-10 may be strain- specific. Considering the enormous toll on human 
health, the development of more effective vaccines and therapeutics is a public health priority. A 
better understanding of host factors that mediate protective immunity as well as drive pulmonary 
damage is undoubtedly an important step in the rational design of next generation therapeutics. 
The data presented in this dissertation serves to underscore the importance of mouse models 
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CHAPTER 1: Introduction 
 
1.1 Influenza: Epidemiology, virology and clinical features 
Influenza is a globally important respiratory pathogen that continues to pose a 
significant public health problem. Infecting between 10-20% of the world’s population 
every year, influenza is one the leading causes of infectious respiratory disease today 
(1,2). Seasonal infections result in 3 to 5 million cases of severe disease worldwide 
(World Health Organization WHO factsheet 211: influenza; 2003) and between 17,000-
51,000 deaths in the United States every year (3). The annual economic burden 
associated with these recurrent infections and hospitalizations is estimated to be a 
staggering $87 billion, with a majority of this burden borne by young children and 
individuals over the age of 65 (4). In temperate zones, annual epidemics tend to peak 
during the winter seasons, while in tropical regions infections can occur throughout the 
year. The exact cause for this seasonality is not clear.  
Influenza viruses are unique in terms of their ability to cause recurrent annual 
epidemics as well as more serious pandemics. Due to low pre-existing immunity to 
newly emergent influenza strains, pandemic influenza viruses have the capacity to infect 
a much larger proportion of individuals and cause morbidity and mortality on a global 
scale. It is estimated that the 1918 pandemic “Spanish flu” resulted in the death of 
greater than 50 million people across the world with over 500,000 deaths in the United 
States alone (5). There have been three subsequent pandemic in the last century 
including the 1957 “Asian flu”, 1968 “Hong Kong flu” and 2009 swine-origin H1N1. 
Continued human infections with highly pathogenic avian influenza strains such as H5N1 
and H7N9 virus underscores why efforts to develop new vaccines and antiviral agents 
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has remained a public health priority for over 50 years. Such efforts, however, hinge on 
a detailed understanding of virus biology, the host response to infection/vaccination and 
mechanisms adapted by the virus to evade host defenses.  
The focus of the work presented in this dissertation is to advance our understanding 
of the host immune response to influenza vaccination and infection using human 
samples and mouse models of disease. The goal of the first chapter of this dissertation 
is provide the reader with an understanding of the current thinking regarding the immune 
mechanisms that drive protective and pathologic responses to influenza viruses. I will 
begin by providing an overview of influenza virus biology, antigenic diversity and clinical 
characteristics. I will then describe the current understanding of protective immunity to 
influenza and its utility in guiding vaccine design. This will be covered partly in Sections 
1.2, 1.3 and 1.4. The second theme will focus on pathologic responses that lie at the 
heart of influenza pathogenesis and how understanding regulatory mechanisms that limit 
such responses can be beneficial in identifying new targets for intervention. This will be 





1.1.1 Virus biology and antigenic diversity 
Influenza viruses are negative strand RNA viruses of the Orthomyxoviridae family 
and can be divided into three viral types: A, B and C (6). Of these, influenza A viruses 
exhibit the greatest genetic diversity and account for the vast majority of severe disease 
in humans and will therefore be the focus of this chapter. Influenza A viruses contain 8 
single stranded, negative-sense, RNA gene segments that encode at least 11 proteins 
as shown in Fig 1.1 (adapted from (7)).  
 
Figure 1.1  The structure of influenza A virus 
Fig 1.1 The genome 
of influenza A virus is 
composed of 8 gene 
segments and are 
listed from largest to 
smallest by 
convention. The first 
three gene segments 
(PB2, PB1 and PA) 
encode proteins that 
form the viral 
polymerase. The 
gene segment 
encoding PB1 also 
encodes a small 
mitochondrial protein 
PB1-F2 that is 
translated in another 
reading frame. Two segments encode the major surface envelope glycoprotein: Hemagglutinin (HA) which is 
responsible for receptor binding and entry into host cells and Neuraminidase (NA) which is responsible for 
budding new virions from infected cells. A single segment encodes nucleoprotein (NP) which binds the viral 
RNA. The seventh segment encodes two proteins: the matrix protein (M1) which serves as a major viral 
capsid protein and M2, a membrane protein that serves as an ion channel. The last segment also encodes 
two non-structural proteins: NS1 and NS2.  
 
 
Influenza A viruses are further divided into subtypes based on the genetic sequence 
and serology of the two major surface glycoproteins: hemagglutinin (HA) and 
neuraminidase (NA). There are currently 17 known HA (H1-H17) and 10 known NA (N1-
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N10) subtypes (8).  Viruses bearing all known HA and NA subtypes have been isolated 
from their natural reservoir, wild waterfowl. Avian influenza preferentially replicates in 
cells lining the intestinal tract of aquatic birds causing no symptoms or disease. The 
virus is then excreted in high concentrations in the feces and is thereby easily 
transmitted to other aquatic birds through the water supply (9).  The avirulent nature of 
avian influenza infections in their natural hosts (wildfowl and shore birds) is likely due to 
centuries of virus adaption to this host. Interestingly, phylogenetic analysis of amino acid 
changes show that avian influenza viruses have low evolutionary rates with no evidence 
of net evolution over the last 60 years, suggesting that the virus may be in evolutionary 
stasis in this host (10). Occasionally, these avian subtypes can transmit to other species 
causing isolated outbreaks or can establish themselves in the new host. So far, avian 
influenza viruses have been shown to cause outbreaks in domestic poultry (such as 
chicken) and mammals including seals, whales, pigs and humans (reviewed in (11)).  
In humans, the process by which new influenza subtypes carrying a novel 
hemagglutinin (or a novel hemagglutinin and neuraminidase) that is immunologically 
distinct from those of circulating influenza viruses, appear in the human population is 
called antigenic shift. Antigenic shift is thought to occur through the genetic reassortment 
of gene segments between human and avian influenza subtypes (12). Transmission 
from aquatic birds to humans was initially thought to require an intermediate animal host, 
such as pig, which can be infected by both human and avian species. However, recent 
infections of humans with the highly pathogenic H5N1 subtype as well as H7N9 suggest 
that domestic poultry, such as chicken and duck, can also serve as an intermediate host 
(13,14). Should the newly transmitted virus acquire the ability to be efficiently transmitted 
from person-person, a pandemic ensues. Due to the sheer number of influenza subtypes 
present in avian species as well as the large number of animal and avian reservoirs, 
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developing vaccines and other reagents against all influenza strains is not a feasible 
option (12). Thus increased surveillance of domestic birds and animals to detect new 
influenza subtypes as well as developing reagents, particularly vaccines that are 
effective across multiple different strains will be crucial in pandemic preparedness 
efforts. The latter will be discussed in more detail in coming sections.    
Once established in the mammalian host, unlike avian viruses, mammalian influenza 
strains constantly undergo mutations by a process called antigenic drift. This occurs in 
both influenza A and B viruses (reviewed in (15)). Antigenic drift is a process by which 
the virus gradually accumulates point mutations including its two major surface proteins 
HA and NA. The mutations can be substitutions, deletions or insertions and occur 
throughout the viral genome resulting in the generation of antigenically divergent strains. 
Antigenic drift occurs because the viral RNA polymerase that transcribes the viral 
genome lacks proof reading activity thereby allowing non-deleterious point mutations to 
occur at a rate of roughly 1/104 bases per replication cycle (16). The host humoral 
response selects for mutants with changes to HA and NA as these strains are able to 
avoid the neutralizing antibody response established by previous infection or 
vaccination, thereby allowing the generation of new seasonal variants capable of 
causing repeated infections in humans. 
In humans, unlike avian species, influenza is primarily a respiratory disease (17). 
Person-to-person transmission occurs through aerosolized droplets generated by 
coughing, sneezing or talking. After inhalation, the virus gets deposited onto the 
respiratory tract, where it primarily infects the columnar epithelial cells of the upper 
respiratory tract.  Influenza virus infection is mediated by binding of the receptor binding 
domain of the surface HA protein to the sialic acid (SA) present on glycans on the 
surface of host cells (18). The preference of HA subtypes to bind specific SA moieties is 
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important in determining host range and tissue tropism. Human adapted influenza 
viruses preferentially bind terminal SA linked to galactose by an 2,6 linkage, which are 
abundant in the respiratory epithelium of human airways (19-21). Avian influenza 
viruses, on the other hand, preferentially bind SA linked to galactose by an 2, 3 linkage, 
present on the respiratory and intestinal tracts of aquatic birds.   After attachment, the 
virus enters the cell by endocytosis as shown in Fig 2 (22). In the low pH of the 
endosome, the virus undergoes a conformational change thereby facilitating the fusion 
of the viral and endosomal lipid membranes releasing the viral ribonucleoproteins 
(RNPs) into the host cell cytoplasm (23). Once in the cell, viral RNPs are transported to 
the nucleus for vRNA replication and mRNA transcription using cellular machinery. Viral 
mRNAs are transported to the cytoplasm for translation into structural and non-structural 
proteins whereas vRNAs are translocated to the cytoplasm for virion assembly (24-26). 
Once assembled at the surface of the host cell, NA is required for release of the budding 
virion by cleaving the SA receptors facilitating the release of new virions (27). 
Figure 1.2  Schematic diagram of influenza virus life cycle 
 
                                                From Neumann, G., et al.2009. Nature. 459: 931-939 
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Fig 1.2. After receptor-mediated endocytosis, the low pH of the endosome releases the viral RNA into the 
cytoplasm. Viral RNA is then transported to the nucleus wherein viral replication and transcription is carried 
out by the polymerase complex (PB1, PB2, and PA) and the nucleoprotein (NP). Messenger RNAs are 
transported to the cytoplasm for translation and early proteins that are required for transcription and viral 
replication are transported back to the nucleus.PB1-F2 associates with the mitochondria and is thought to 
induce apoptosis. Later in the viral life cycle, late proteins such as NS2 (also known as nuclear export 
protein or NEP) and the matrix protein M1 transport newly synthesized viral ribonucleoproteins from the 
nucleus. Virion assembly occurs at the host cell membrane and budding is facilitated by the neuraminidase 
activity of NA. 
 
1.1.2. Clinical features of uncomplicated and complicated influenza 
Seasonal influenza infections can vary in severity from subclinical infections to 
severe febrile illness (28). In adults and adolescents, influenza typically presents as a 
sudden onset of high-grade fever (38-40C) with symptoms including chills, myalgia, dry 
cough, sore throat and headache. Bronchial airway hyper-reactivity and small-airway 
dysfunction are also common features. The fever peaks within the first 24 hours of 
infection and can last between 1-5 days during which time infectious virus particles are 
actively shed. These clinical features of uncomplicated influenza are generally 
indistinguishable from those of other respiratory viral infections. In children, 
gastrointestinal symptoms including nausea, vomiting, abdominal pain and diarrhea are 
also common (29) (30).  While most healthy adults experience an acute infection that 
typically does not require medical intervention, chronic underlying medical conditions 
such heart and lung disease, diabetes and stroke can increase the risk of developing 
complications (31). Every year complications due to influenza infections are estimated to 
cause 36,000 deaths and more than 200,000 hospitalizations in the United States (2,32). 
The most frequent serious complications of influenza occur in the lung and fall into three 
main categories:  primary viral pneumonia, secondary bacterial pneumonia and 
exacerbation of chronic pulmonary diseases. 
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Primary influenza pneumonia was first identified during the 1958-1959 pandemic (33) 
and is associated with a high mortality rate (6-20% during interpandemic periods) 
(34,35). Viral pneumonia can begin as early as 24 hours after the onset of febrile illness 
and is characterized by tachypnea, diffuse rales, cyanosis and ultimately respiratory 
failure (6,31). Unfortunately, patients often deteriorate despite treatment with antivirals. 
Histopathological findings in pure viral pneumonia include necrotizing bronchitis, intra-
alveolar hemorrhage, edema and interstitial inflammation (36).  
Secondary bacterial pneumonia was first identified during the 1918 pandemic and is 
characterized by the re-appearance of fever, dyspnea and productive cough during the 
convalescent phase of infection (37,38). The most common pathogens associated with 
secondary bacterial pneumonia are Staphylococcus aureus, Haemophilus influenzae 
and Streptococcus pneumonia (39). Like primary viral pneumonia, secondary bacterial 
pneumonia can also be associated with a high mortality rate of about 33% and has been 
observed during subsequent pandemics and seasonal epidemics. 
In addition to pneumonia, influenza infections exacerbate pre-existing chronic 
pulmonary conditions such as chronic obstructive pulmonary disorder (COPD) and cystic 
fibrosis leading to excess morbidity and mortality in these patients (40). The exact 
mechanisms that underlie this process are not well understood (41).  
 
1.2 The immune response to influenza 
The severe lung disease caused by influenza, described in the previous section, 
poses a great challenge to the immune system: the host has to mount an effective 
immune response to rapidly eliminate the virus but tissue inflammation must be 
controlled to prevent immunopathology and respiratory failure. In this section, I will 
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review our current understanding of the role of innate and adaptive immunity in 
mediating protection from influenza. This summary will also serve as a primer for the 
next section on influenza vaccines and vaccine evaluation.  Finally, I will discuss the role 
of the host immune response in the pathogenesis of severe influenza and highlight the 
importance of immune regulation in preventing the development of pulmonary injury. 
 
1.2.1 The innate immune response 
The cellular network of the lower respiratory tract (including the trachea, bronchi and 
lungs) is made up of CD45+ hematopoietic cells as well as CD45- stromal cells including 
various types of respiratory epithelial cells and fibroblasts. Of these, alveolar epithelial 
cells and epithelial cells lining the conducting airways serve as the primary target for 
influenza virus infection (42,43). Upon infection of permissive cells, the virus is first 
detected by cellular sensors namely, Toll-like receptors (TLRs), retinoic inducible gene I 
(RIG-I)-like receptors (RLRs) and nucleotide oligomerization domain (NOD)-like 
receptors (NLRs), specifically NLRP3 (44,45). Engagement of these receptors on 
epithelial cells and resident innate immune cells including NK cells, lung resident 
dendritic cells (DCs) and alveolar macrophages activates them and triggers the release 
of pro-inflammatory cytokines including Type-1 interferons, IL-1β, IL-18, IL-6, TNF-α, IL-
8 and chemokines such as CCL2 (reviewed in (46)). In humans, presentation of 
symptoms associated with influenza virus infection typically coincides with the onset and 
magnitude of the host innate immune response (47). IL-6, TNF-α and type 1 interferons 
(IFN-α) can be detected in symptomatic individuals both from nasopharyngeal washes 
as well as in serum and have been found to correlate with symptom score and body 
temperature (48).  
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The release of soluble mediators during the early phase of infection serves to 
enhance the antiviral capacity of infected cells and promotes the recruitment of 
inflammatory cells from blood and even distal compartments such as the bone marrow 
(49-51). Indeed, recruitment of NK cells (52), macrophages and neutrophils (53) have 
been shown to be critical in the control of viral replication. In addition to mediating early 
viral control, the innate immune response also plays a key role in regulating the 
development of adaptive immunity. Several pulmonary antigen-presenting cell (APC) 
populations including pDCs, monocyte derived DCs, alveolar macrophages and most 
notably resident alveolar and interstitial DC populations are thought to be important in 
the presentation of antigen to T cells in the draining lymph nodes (reviewed in (46) and 
(54)). In the case of lung resident DC’s, virus uptake, either through phagocytosis of 
dying epithelial cells (55) or direct infection (56), triggers their mobilization and migration 
out of the lung. This process is also aided by cytokines such as type 1 interferons, IL-12 
and TNF-α, which enhance DC maturation and migration (54,57). Activated migratory 
DCs upregulate the expression of costimulatory and adhesion molecules like CD80, 
CD86, CD40 and ICAM-1 as well as antigen presenting molecules making them potent 
APCs for the activation of the adaptive immune response. 
 
1.2.2. The adaptive immune response 
Cellular immunity 
The migration of antigen-bearing mature APC’s to the lymph nodes serves to 
activate naïve (and memory) T cells. Following their encounter with mature APC’s, 
antigen-specific T cells undergo activation and proliferation and traffic to the lung as 
highly differentiated effectors, reaching peak numbers by 7-8 days post infection (58). In 
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the lung, activated CD4 and CD8 T cells mediate direct clearance of infected cells 
through multiple synergizing mechanisms including secretion of effector cytokines such 
as IFN-γ and TNF-α, exocytosis of cytolytic molecules such as perforin and granzyme 
and the expression of cell-death ligands such as Fas-L and TRAIL (59-61). In addition, 
CD4 T cell help is also thought to be critical for the generation of long-lived memory B 
cell and antibody responses required for effective and rapid clearance during re-infection 
(62-64). Following clearance of virus, there is a rapid contraction of antigen-specific T 
cells leaving only a small number of memory cells that can persist long term (65). The 
memory T cell response to re-infection has been shown to have a profound effect on 
protection in two primary ways:  
 
1. T cell mediated “help” for antibody production 
Recently, a dedicated subset of T follicular helper (TFH) cells that are required for the 
formation of germinal centers and the generation of long-lived serological memory were 
described (reviewed in (66) and (67)).  Germinal center TFH cells have been shown to be 
required for the maintenance and proliferation of germinal center B cells and for the 
differentiation of germinal center B cells into plasma and memory B cells. In animal 
studies and recently in humans, induction of TFH cells by vaccination has been found to 
correlate with increased antibody production (68,69).  
The generation of long-lived B cell memory is critical to the prevention of re-infection 
and is the goal of most current vaccination strategies and will be described in more detail 
in the following section. As illustrated above, the induction of T helper cells responses is 
increasingly recognized as being critical to this process and could be an important part 
of new vaccine efforts, particularly in vulnerable populations such as the elderly where 




2. Direct control of viral replication 
In addition to providing “help” for antibody production, T cell memory has been 
shown to play an important role in mediating direct control of viral load. Antigen specific 
memory CD4 and CD8 T cells are recruited to the site of infection within 2-3 days 
following secondary challenge and can rapidly produce effector cytokines upon cognate 
antigen recognition (71,72). The early production of cytokines and chemokines serves to 
mobilize and activate innate cells, which can further contribute to control of viral 
replication (73,74).  
Epitope mapping efforts suggest that unlike antibodies, which primarily recognize 
epitopes from the highly variable surface proteins (HA and NA), T cells recognize 
epitopes derived from the internal proteins of the virus that are more conserved between 
divergent influenza strains (75). Indeed, in animal models of infection, T cells have been 
shown to be the primary mediators of cross-protective or heterosubtypic immunity (76). 
Despite studies demonstrating the importance of memory T cells in protective immunity, 
particularly cross-reactive immunity to influenza in animal models, until recently, 
relatively little was known about their importance in human disease. Influenza-specific T 
cells can be readily detected in peripheral blood in healthy adults, however, evidence for 
a role in protective immunity is sparse and largely circumstantial. In early studies of 
experimentally infected humans, cytotoxic T cells correlated with viral clearance in 
individuals lacking antibodies, although these studies did not distinguish CD4 and CD8 T 
cells (77). More recently, in a controlled challenge study, pre-existing memory CD4 T 
cells were found, for the first time, to be associated with protection from disease in the 
absence of neutralizing antibodies (78). The magnitude of the CD4 T cell response to 
infection correlated with reduced viral shedding, reduced disease severity and duration. 
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Consistent with findings in animal models (79), influenza specific CD4 T cells were able 
to exert direct cytolytic effects on infected cells.  In humans, numerous studies have 
demonstrated the existence of pre-existing memory CD4 and CD8 T cells that recognize 
influenza subtypes to which individuals have had no prior exposure (75,80). A recent 
study with over 300 participants showed that the frequency of pre-existing cross-reactive 
memory CD8 T cells correlated inversely with symptom score during the 2009 pandemic 
(81). This landmark study is the first to demonstrate the importance of these cross-
reactive T cells in mediating heterotypic protection against newly emergent strains in 
humans. These studies strengthen the argument that harnessing cross-reactive cellular 
immunity maybe of great benefit in designing vaccines to combat newly emergent 
influenza subtypes. 
 
Humoral immunity  
Like T cells, B cells responses are also primarily induced in the draining lymph nodes 
either through interaction with antigen-bearing DCs or through direct uptake of antigen 
(82-84). In mice, antibody forming cells can be detected as early as 3 days after infection 
in the draining lymph nodes and are soon followed by the presence of neutralizing 
antibodies in nasal and lung lavages. Neutralizing antibodies directed against the 
globular head of the surface hemagglutinin (HA) are considered the most effective 
mediators of protection against influenza and are the widely used as the primary immune 
correlate of protection from re-infection in humans (85). However, due to the highly 
variable nature of the globular head of HA, anti-HA antibodies have been shown to be 
largely strain-specific. Interestingly, several recent studies have identified antibodies that 
recognize epitopes derived from the more conserved stalk region of HA as well as 
epitopes from other conserved proteins including M2 (86-88). While the relative 
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contribution of these cross-reactive antibodies to protective immunity during natural 
infection in humans is still unclear, there is interest in developing vaccines that can 
selectively induce antibodies to such well conserved epitopes and is discussed further in 
section 1.3.5. 
 
1.2.3 Regulating the immune response to influenza 
The development of an effective immune response (as described above) is critical to 
viral control and prevention of virus mediated lung injury. However, appropriate 
regulation of the immune response is as important in preventing host-mediated 
immunopathology.  In this section, I will provide a review of data that implicate the 
immune response as central to influenza pathogenesis as well as highlight the current 
understanding of regulatory mechanisms that govern this process. 
Despite their critical role in controlling viral replication, studies in animals as well as 
humans suggest that the host immune response maybe instrumental in causing 
pulmonary pathology during seasonal and pandemic influenza infections.  Experimental 
studies in mouse and non-human primate models demonstrate a profound and early 
over-expression of cytokines and chemokine after infection with highly virulent strains of 
influenza (89).  Similarly, individuals who succumbed to disease either during infection 
with the highly pathogenic H5N1 virus or during severe seasonal infections had high 
levels of proinflammatory mediators including IL-6, CCL2, CXCL10 (IP-10) and IL-8 (90) 
(91) (92).  This phenomenon is referred to as the “cytokine storm” and has been 
observed with other acute respiratory viruses including those in the coronavirus family 
(severe acute respiratory syndrome virus - SARS and Middle East Respiratory 
Syndrome coronavirus – MERS-CoV) (93,94). Uncontrolled production of chemokines, 
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particularly CCL2, has been found to induce increased recruitment of innate immune 
cells such as monocytes/macrophage and NK cells into the lung, which in turn release 
more cytokines, thereby exacerbating the cytokine storm (95,96). The increased 
recruitment of TNF-α and iNOS producing dendritic cells in particular has been shown to 
be associated with severe influenza in animal models (97). This exacerbated 
proinflammatory response is believed to contribute to severity of the disease by leading 
to host-mediated collateral damage of host tissue, acute respiratory distress syndrome 
(ARDS) and multiple organ failure (98,99).  
Undoubtedly, stringent regulation of the above-described inflammatory response is 
critical to minimizing immunopathology and both innate and adaptive immune cells have 
been found to contribute to this process. As mentioned previously, neutrophils are 
thought to be important contributors to tissue pathology during influenza. However, in 
mice, neutrophil depletion during influenza led to exacerbated pulmonary inflammation, 
edema and hemorrhage suggesting that neutrophils may also play a regulatory role 
during infection in vivo, although the exact mechanisms remain unclear (53,100). 
Similarly, lung epithelial cells have been shown to express the macrophage inhibitory 
molecule CD200 to dampen down pulmonary inflammation (101). Classically activated 
macrophages are thought to play a role in pulmonary injury by secreting high levels of 
inflammatory mediators (102). However, two other populations of macrophages have 
been described in the literature, namely wound healing macrophages and regulatory 
macrophages, together referred as alternatively activated macrophages (103). Activation 
of the nuclear receptor peroxisome proliferator activated receptor (PPAR)-γ, an 
important regulator of the alternatively activated phenotype (104), seems to alleviate 
pulmonary inflammation during lethal influenza infection, suggesting that alternatively 
activated macrophages may play a role in resolution of inflammation (97,105). However, 
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more studies are required to better understand if and how alternatively activated 
macrophages control tissue damage during influenza. 
The anti-inflammatory cytokine, IL-10, has long been recognized as one of the most 
potent negative regulators of the immune system. It is expressed by a wide variety of cell 
types including macrophages, neutrophils, epithelial cells, B cells and importantly T cells 
(reviewed in (106)). IL-10 is thought to act primarily through the suppression of APC 
function and activation, thereby limiting proinflammatory cytokine secretion and induction 
of Teffector cells. Although IL-10 is critical in controlling inflammation and tissue damage 
during several infectious as well as autoimmune diseases, surprisingly little is known 
about its role during influenza infections in humans or animal models. Somewhat 
unexpectedly, several recent studies show that expression of IL-10 is associated with 
severe disease and poor outcomes during influenza infections in humans (107-109). In 
animal models, the role of IL-10 is less clear with one study demonstrating a protective 
role for IL-10 (110) while others have reported a pathogenic role (111,112). Resolving 
these conflicting data will be important to better understanding regulatory mechanisms 
that govern the development of protective pulmonary responses versus 
immunopathology.  This will be the focus of the 4th chapter of this dissertation.  
As mentioned previously, infection with influenza results in the loss of respiratory 
epithelial cells resulting in significant respiratory dysfunction (reviewed in (113)). Exciting 
new research suggests that a rare population of immune cells termed innate lymphoid 
cells (ILCs) may play a critical role in the repair of this tissue injury (114). ILCs can be 
broadly divided into 3 functional categories: NK cells, RORγt+ ILCs and type 2 ILCs 
(ILC2). IL-22 expressing NK cells (115) as well as ILC2 that make T helper 2 (TH2) 
cytokines including IL-4, IL-5 and IL-13 (116) have been found to be important in 
regulating epithelial integrity and promoting tissue homeostasis after infection with 
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influenza. Importantly, similar observations have been made in other mucosal tissues 
(117,118) as well as in non-infectious models of injury (119). These data suggest that 
this may represent an evolutionarily conserved mechanism to maintain and promote 
barrier integrity at mucosal sites and warrants further study. 
Targeting host inflammatory and/or repair pathways represents an exciting 
opportunity to limit tissue injury associated with infectious or chronic inflammatory 
conditions. We are just beginning to appreciate that immune cell signaling not only 
controls the initiation of inflammation but may also play a critical role in the initiation of 
tissue repair and remodeling. Understanding these divergent yet related pathways is 
critical to the identification of new targets for therapeutic manipulation.  
   
1.3 Vaccines 
Vaccines are currently the most effective means to control the burden of influenza 
(6). While originally thought to confer protection to between 60-90% of vaccine 
recipients, emerging data suggest that vaccine efficacy maybe lower than previously 
thought, particularly in vulnerable populations. This section is intended to provide a 
review of the current strategies for commercial seasonal influenza vaccine manufacture, 
vaccine efficacy and effectiveness as well as new strategies that are under investigation 
to improve vaccine efficacy. Finally, I will discuss vaccine evaluation strategies as an 
important aspect of new vaccine development. 
The current seasonal influenza vaccines are designed to induce strain-specific 
neutralizing antibodies against the variable HA protein (85). To account for the constant 
drift within HA, the seasonal vaccines are reformulated ever year based on year-round 
global surveillance of influenza strains in the population, accomplished through the WHO 
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Global Influenza Surveillance and Response System (120). Once the dominant 
circulating strains have been identified, WHO collaborating centers generate a vaccine 
seed strain through genetic re-assortment of a master strain and the field strains, which 
are then distributed to the vaccine producers.  
In the United States, there are currently three types of influenza vaccine formulations 
that are available commercially: inactivated influenza vaccines, live attenuated influenza 
vaccines and a recombinant influenza vaccine (which will become available for 
distribution during the 2013-2014 influenza season)(121). Commercially available 








1.3.1 Inactivated influenza vaccines 
The inactivated influenza vaccine first became approved for use in the United States 
in 1945 and is still widely used today (122).  The vaccines were originally produced by 
propagation of influenza viruses in embryonated hens’ eggs followed by inactivation and 
purification.  Today, inactivated influenza vaccine seed strains are obtained by re-
assorting the HA and NA of field strains with internal gene segments from a “high 
growth” master donor strain (A/Puerto Rico/8/34) (123).There is no “high growth” 
influenza B master donor strain currently available. While the majority of inactivated 
vaccines are still produced by propagating the vaccine seed strain in hens’ eggs, 
depending on the extent of purification, the inactivated vaccines can be divided into 3 
types: whole virus, split and subunit vaccines. In the United States, none of the 
commercially available vaccines contain adjuvants. 
 
1. Whole virus vaccines 
Whole-virus inactivated, unadjuvanted vaccines are manufactured by inactivating 
purified vaccine seed strains with formaldehyde or β propiolactone (BPL) followed by 
purification.  While whole-virus vaccines are reported to be more immunogenic in naïve 
populations and are still used in some countries, they have been associated with a 
higher frequency of adverse reactions compared with other influenza vaccines, 
particularly in children (123). Therefore, they are estimated to account for less than a 





2. Split vaccines 
The majority of inactivated influenza vaccines are “split” by treating the purified 
vaccine seed strain with a detergent such as Triton X-100, sodium lauryl sulphate or 
Tween 80 to extract proteins from the lipid membranes. The preparation is then further 
purified and the HA rich fragment is harvested. The split vaccines are administered 
intramuscularly with the most commonly reported adverse events being injection site 
reaction followed by pain, fever, myalgia and headache (124). In 2011, the US FDA 
approved Sanofi Pasteur’s Fluzone® intradermal vaccine (125).  
 
3. Subunit vaccines 
The preparation of subunit vaccines is very similar to that of split vaccines, but more 
rigorous purification is carried out so that the vaccine consists almost exclusively of the 
purified HA and NA subunits with minimal contaminating N, matrix protein, nucleoprotein 
and lipid. All subunit vaccines are currently administered intramuscularly.  
  
1.3.2 Live attenuated influenza vaccines (LAIV) 
The first intranasally delivered, live attenuated influenza vaccine (FluMist) was 
licensed in the United States in 2003 and was developed to more closely resemble 
natural infection compared to the parenterally delivered inactivated vaccines (126). The 
live attenuated seed vaccine strains are constructed by re-assorting the HA and NA 
gene segments from circulating influenza strains with 6 gene segments from a master 
donor strain which is temperature sensitive (ts), cold-adapted (ca) and attenuated (att). 
In the United States, two master donor strains are used in the commercial manufacture 
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of FluMist : A/Ann Arbor/6/60 and B/Ann Arbor/1/66. The most common side effect 
after administration of LAIV is runny nose and nasal congestion (127,128). 
  
1.3.3 Recombinant influenza vaccines 
A new recombinant trivalent influenza vaccine (Flublok) was approved in 2013 and 
will be available for distribution during the 2013-2014 influenza season. Unlike existing 
influenza vaccines that involve growing influenza viruses in hens’ eggs or mammalian 
cell lines, requiring longer production time and are costly, the recombinant vaccine is 
manufactured by expressing each of the three selected HAs in a continuous insect cell 
line using a baculovirus expression system. The HAs are then extracted using Triton X-
100 and purified by column chromatography before packaging                                       
(http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UC
M336020.pdf).   
 
1.3.4 Efficacy and effectiveness of seasonal influenza vaccines 
Early estimates of seasonal influenza vaccine efficacy suggested that the seasonal 
influenza vaccines were between 70-90% effective in preventing seasonal influenza-like 
illness (123,129-132). However, the true effectiveness of seasonal vaccines has recently 
been the topic of intense debate with a recent meta-analysis revealing much lower 
vaccine efficacy than previously thought ((133)). In this section, I will outline the most 
current information regarding the efficacy of the seasonal trivalent inactivate vaccine 






In the United States, inactivated influenza vaccines are recommended for all children 
>6 months of age whereas LAIV is only approved for use in children older than 2 (134). 
Studies with age-specific data suggest limited effectiveness of the inactivated vaccine 
against medically attended, laboratory-confirmed influenza in children with the lowest 
vaccine effectiveness (7%-52%) noted in children aged 6-59 months (123,135-138).  In 
years of suboptimal antigenic match between vaccine and circulating strains, the 
inactivated vaccine was not found to be significantly effective against influenza related 
illness.  
On the other hand, LAIV has been found to be highly efficacious in young children, 
providing significant protection  (pooled vaccine efficacy of 83%) against laboratory-
confirmed influenza in years with good antigenic match but importantly even in years 
when there was suboptimal match between circulating and vaccine strains (133).  
Adults <65 
In healthy, young adults, seasonal TIV and LAIV were previously shown to prevent 
laboratory confirmed influenza in 70%-90% of healthy adults under 65 years of age 
(130,139). However, a recent meta-analysis of ten randomized controlled trials over 
twelve influenza seasons suggests that the pooled vaccine efficacy of TIV in preventing 
laboratory-confirmed influenza was only 59% (133). This analysis is supported by more 
recent data from observational studies suggesting lower effectiveness of TIV in 
preventing influenza infections in healthy adults (140). Additionally, efficacy and 
effectiveness in preventing illness have been shown to be substantially lower in studies 
conducted during influenza seasons when the vaccine and circulating strains were not 
antigenically matched (131). Surprisingly, no protective efficacy was observed after LAIV 
in any of the randomized controlled trials (133).  
24 
 
Vaccine effectiveness among adults with chronic diseases has also been shown to 
be lower than that for healthy adults (123). 
Adults >65 
Adults>65 represent an important population who account for more than 90% of the 
mortality associated with seasonal epidemics every year (141). Currently only the 
inactivated vaccine is approved for use in this population. A recent review of the efficacy 
of effectiveness of seasonal vaccination suggests that in elderly individuals living in the 
community, vaccines were not significantly effective against influenza, influenza-like 
illness or pneumonia  (142) and were only moderately effective (vaccine effectiveness 
23%) against influenza-like illness in elderly living in nursing homes and long-term care 
facilities. Consistent with poor effectiveness in preventing illness, the current vaccines 
have also been shown to induce weak antibody responses in the elderly (134). In an 
effort to increase immunogenicity and vaccine effectiveness, a high dose formulation has 
recently been approved for use in individuals over 65 (143). The higher dose 
preparations have been shown to be more immunogenic and elicit a significantly higher 
antibody response although their effectiveness in preventing infection is yet to be 
determined. An MF59 adjuvanted vaccine (FLUADTM Novartis) has also been developed 
primarily for use in the elderly. Interestingly, early clinical studies indicates significantly 
enhanced protection against influenza in this population (144).  
Taken together, these data suggest while the current vaccines are efficacious in 
preventing infection under certain circumstances, over all there is a need for more 
effective vaccines. In the next section, I will outline some of the advances in the 




1.3.5 Advances in seasonal and pandemic influenza vaccines  
As detailed above, even when influenza vaccines are well matched to circulating 
viruses, their effectiveness in preventing illness in individuals who are at the greatest risk 
of severe disease, namely the elderly, young children and individuals with underlying 
medical conditions is thought to be low (133,134,136). Even in healthy adults, vaccine 
efficacy in preventing febrile illness has recently been shown to be lower than what was 
previously shown. In addition, the current vaccines are thought to be poorly efficacious 
against newly emergent or drifted influenza strains making yearly reformulation of 
seasonal vaccines a necessity.  In the event of an influenza pandemic, as was observed 
in 2009, there can a significant delay between the emergence of a pandemic strain and 
the development of an effective pandemic vaccine, partly due to production time 
required for current egg-based technologies.  For these reasons, there is considerable 
interest in the development of more immunogenic and broadly cross-reactive vaccines 
for use in all age groups. Recently, a self-assembling influenza nanoparticle vaccine that 
can offer broadly cross-reactive immunity has been described (145). An advantage of 
the virus-like particle (VLP) approach over existing platforms is that manufacture of VLP 
vaccines does not require live influenza viruses for development or manufacture. 
Additionally, they are predominantly produced using a baculovirus/insect cell-expression 
system that serves as high-yielding low-cost commercial alternative to egg-based or 
mammalian cell line-produced influenza vaccine approaches. 
Adjuvants represent an important means to enhance the immunogenicity of 
vaccines. Use of adjuvants in vaccine formulations has been shown to allow dose 
sparing, promote epitope spreading and enhance immunogenicity of the vaccines 
(146,147).  While, in the United States, the seasonal influenza vaccines are 
unadjuvanted, oil-in-water emulsion adjuvants (MF59) for pandemic and seasonal 
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influenza are currently used in over 20 counties around the world (148). The success of 
MF59 has promoted research into other oil-in-water formulations. In addition, TLR 
agonists are also being tested for safety and immunogenicity (149).  
The development of the so-called “universal” influenza vaccine which can offer 
cross-reactive immunity against multiple influenza subtypes is the holy grail of influenza 
vaccines. There are broadly speaking two approaches that are actively being pursued to 
achieve this goal: antibody-based strategies and T-cell based strategies. Antibody-based 
strategies aim to induce antibodies against conserved regions of surface protein, 
including the stem region of HA (145,150) and extracellular domain of M2 (151). Pre-
clinical studies in small animals show that antibodies against the conserved regions of 
surface proteins have the ability to prevent infection from a number of influenza subtypes 
(152). However, a recent study demonstrated that antibodies binding to conserved 
regions of HA may enhance fusion with host cell membrane, thereby highlighting a 
potential limitation of such an approach (153).  
The second strategy is based on recent findings in humans that point to an important 
role for T cells in mediating protective and most notably cross-reactive immunity to 
influenza (78,81). However, our limited understanding of the induction and maintenance 
of T cell memory, particularly in humans will be a major challenge in the design of such T 
cell inducing vaccines. To this end, the goal of chapter 3 of this thesis was to 
characterize influenza-specific T cell responses in humans as well as examine the 
impact of different vaccination strategies on T cell immunity.  
A major component of new vaccine development efforts is identifying quantitative 
measures of immunological responses that correlate with protection (154). In the next 
section, I will describe the current paradigm that governs clinical vaccine evaluation as 




1.3.6 Vaccine evaluation and correlates of protection 
Currently, anti-HA antibodies are the only established immune correlate of protection 
and are the gold standard for measuring vaccine immunogenicity. Antibodies against 
influenza are routinely measured in the serum by the hemagglutination inhibition assay 
(HAI). Numerous studies have shown that on a population level, pre-exposure HAI titers 
of > 32 to 40 are associated with protection from re-infection and is often referred to as 
the seroprotective titer (155,156). In fact, the higher the HAI titer, the higher the rates of 
protection (157). Due to the strong correlation between HAI titers and protection from 
infection, the current vaccines are evaluated almost exclusively on the basis of their 
ability to induce a 4-fold increase in serum antibody titers against vaccine strains 
following vaccination compared to pre-vaccination titers.  More recently, however, it has 
been recognized that such serological endpoints may not fully reflect vaccine 
immunogenicity or accurately predict protection from infection. In support of this, a 
recent study found high HAI titers in individuals who were not protected following 
vaccination with TIV or LAIV suggesting that in addition to quantity, perhaps the quality 
of the antibody response may dictate protection from infection (158). Alternatively, 
immune parameters besides antibodies may contribute to protective immunity (85). This 
maybe particularly relevant in the case of LAIV, wherein serum antibody titers do not 
correlate with protection from infection (134). Despite being as efficacious as TIV in 
preventing infection (127), several groups have noted poor serum antibody responses in 
LAIV recipients suggesting that mucosal antibodies and/or other immune mechanisms 
such as influenza-specific T cells may contribute to protection after immunization. In fact, 
till date, there are no correlates of protection following LAIV. 
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As mentioned previously, the development of a cross-reactive “universal” influenza 
vaccine is of great interest from a public health standpoint and yet, current influenza 
vaccines are evaluated solely based on their ability to induce strain-specific anti-HA 
antibodies. A more comprehensive evaluation of current and new vaccines in terms of 
their ability to induce cross-reactive responses may help predict their ability to prevent 




CHAPTER 2: Serum antibody and cytokine response to 
TIV and LAIV 
 
2.1 Abstract 
Despite vaccine efforts, influenza outbreaks pose a significant threat to global public 
health. There are two types of commercially available seasonal influenza vaccines in the 
United States: the trivalent inactivated vaccine (TIV), delivered parenterally, and the 
trivalent live attenuated influenza vaccine (LAIV), delivered intranasally. Although both 
vaccines are generally efficacious, the immunologic mechanisms which contribute to 
protective immunity are incompletely understood. Thus, we investigated the effects of 
TIV and LAIV on serum cytokine profiles in healthy adults at 14 and 28 days post-
vaccination over two influenza seasons and examined their relationship to serum 
antibody induction. We found that TIV recipients had a significantly higher sero-response 
rate compared to LAIV recipients, as has previously been shown. Interestingly, 
vaccination with TIV was also associated with a small, yet significant, decrease in the 
levels of IL-8 and TNF- at 14 and 28 days post-vaccination. However, LAIV had no 
impact on serum cytokine levels at these time points. Finally, we examined the 
relationship between baseline serum cytokine levels and antibody responses to TIV (due 
to the poor sero-response rate in LAIV recipients). In TIV recipients, pre-vaccination 
levels of IL-8 were positively correlated with sero-response to TIV. These data provide 
insight into the systemic immune response to different vaccine formulations and/or sites 







Influenza outbreaks remain a major cause of morbidity and mortality worldwide. 
Seasonal influenza A infections result in 3-5 million cases of severe infection and 
between 250,000 and 500,000 deaths around the world annually (159).  In the United 
States alone, approximately 200,000 people are hospitalized every year in seasonal 
outbreaks.  Currently, vaccination is the most effective means to control the spread of 
seasonal influenza (160). Until recently, there were only two types of vaccines available 
in the United States: The live attenuated influenza vaccine (LAIV) which is currently 
approved for use in immune-competent children and adults ranging from 2 to 49 years 
and the trivalent inactivated vaccine (TIV), which is approved for use in most individuals 
including the very young and the elderly. Both vaccines have been shown to be safe and 
anywhere between 40-100% effective in young, healthy adults (134). However, vaccine 
efficacy can be influenced by age, underlying medical conditions as well as antigenic 
similarity between the circulating and vaccine strains  
Since TIV and LAIV differ in both the route of administration (parenteral versus 
mucosal) as well as the formulation (killed versus live), the immune responses to these 
vaccines are likely to be different (160,161). For instance, intramuscular injection with 
TIV has been shown to induce a robust increase in serum antibodies, a widely used 
correlate of protection (162-164). In contrast, vaccination with LAIV induces a 
substantially lower serum antibody response despite conferring similar levels of 
protection from infection in adult vaccine recipients. These data suggest that multiple 
arms of the immune response including T cells, cytokines, and mucosal antibodies may 
contribute to protective immunity, particularly after vaccination with LAIV. However, the 
current vaccines are almost exclusively evaluated based on their ability to enhance 
serum antibody titers. Therefore, our understanding of the immune response to LAIV 
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and TIV is not complete. As new vaccines and delivery strategies are rapidly under 
development to combat seasonal and pandemic influenza as well as other infectious 
diseases, there is an urgent need to identify the immunologic responses which underpin 
efficacious vaccine strategies (15,165). 
Cytokines are important immune mediators that serve to orchestrate the immune 
response to natural infection and vaccination (166). Analysis of cytokines in infected 
animals and humans have provided important clues into the immune mechanisms that 
mediate protection as well as recovery from influenza and other infectious agents (167-
169). In contrast to their wide use in understanding the immune response in a 
pathological setting, changes in cytokine profiles after vaccination have not been well 
characterized. However, studies in both animals and humans have shown that vaccine-
induced changes in serum cytokines correlate with T cell and innate cell activation (170-
172). These data suggest that changes in global cytokine profiles after vaccination may 
provide useful insight into vaccine efficacy and could potentially serve as biomarkers of 
immune activation following vaccination (171-173). Accordingly, in this study we sought 
to understand how different seasonal influenza vaccine formulations/deliveries (i.e. TIV 
and LAIV) influence serum cytokine profiles in healthy adults. We also determined the 
relationship between serum cytokines profiles and the development of antibody 








2.3 Materials and methods 
Study design and human subjects 
A convenience sample of adults between the ages of 18 and 49 were enrolled at 
the influenza vaccine clinic at the Johns Hopkins University Hospital from October 1 until 
November 30 of both the 2006-07 and 2007-08 influenza vaccine seasons.  Participants 
were screened by questionnaire to assess health history including recent acute illness.  
Volunteers were excluded from the study if they reported to be immuno-compromised 
due to chronic illness or medication.  This study was approved by the Institutional 
Review Board of the Johns Hopkins Bloomberg School of Public Health. 
All volunteers provided written informed consent and chose their vaccine type: 
LAIV (Flumist, Medimmune) or TIV (Fluzone, Aventis Pasteur). Immediately prior to 
vaccination (day 0), a venous blood specimen of approximately 50 ml was collected. 
Volunteers were then immunized following current guidelines for influenza vaccination.  
Participants provided additional blood samples at 14 (day 14) and 28 days (day 28) after 
vaccination. Serum was harvested from blood samples using serum separator tubes 
(Becton Dickinson, San Jose, CA) and stored at -80˚C. The 2006-07 seasonal vaccines 
contained A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2) and 
B/Malaysia/2506/2004.  In the 2007-08 season, both vaccines contained A/ Solomon 
Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004.  Each 
dose of TIV contained 45 µg of HA in the recommended ratio of 15 µg from each virus 
strain. Each dose of LAIV contained 106.5 to 107.5 median tissue culture infectious doses 






Hemagglutination inhibition assay (HI) 
HI titers were measured in serum samples for all three vaccine strains in each 
season. Influenza virus strains A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 
(H3N2), B/Malaysia/2506/2004 and A/ Solomon Islands/3/2006 (H1N1) were obtained 
from the CDC.  Serum samples were pretreated with receptor destroying enzyme (Lonza 
Inc., Walkersville, MD) overnight at 37˚C. Samples were then treated with Sodium 
Citrate (1.6%) and heated at 56˚C for 45 minutes. The hemagglutination inhibition (HI) 
assay was performed as described previously (162). Briefly, 25 μl of specific influenza 
virus (4 HA units) was added to 25 μl of serum serially diluted in 2-fold dilutions till 
1:2048 in PBS and incubated for 1 hour at room temperature. 50 μl of 0.5% chicken red 
blood cells (for influenza A H1N1 and influenza B) and turkey red blood cells (for 
influenza A H3N2) was then added and incubated for a minimum of 30 minutes before 
reading the HI activity. All erythrocytes were obtained from CBT farms (Federalsburg, 
MD). The HI antibody titer for a given sample was defined as the reciprocal of the last 
dilution at which there was complete inhibition of HA activity. For example, if the last 
dilution at which there was a complete inhibition of HA activity was 1:4, the titer for the 
given sample was represented as 4.  A titer of 2 was assigned to all samples in which 
the first dilution (1:4) was negative.  
 
Serum cytokine quantification 
Serum cytokines were determined using the Ultrasensitive Human Th1/Th2 10-plex 
from Meso-Scale Discovery (MSD), (Gaithersburg, MD).  The MSD multispot array was 
run according to the manufacturer’s protocol with minor modifications. Briefly, plates 
were pre-incubated with 25 μl of supplied human sera diluents for 30 minutes, with 
shaking, at room temperature. A modified 12-point calibration curve was used instead of 
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the recommended 8-point curve (174). Calibration curves were prepared in the diluents 
and ranged from 2500 pg/ml to 0.15 pg/ml. Following the 30 minute incubation period, 
25 μl of serum sample or calibrator was added to the wells in duplicates. Plates were 
then incubated at room temperature for 2 hours with shaking.  Plates were then washed 
with PBS and 0.05% Tween-20 and then incubated with 25 μl of capture antibody for 2 
hours at room temperature with shaking. After washing plates with PBS and 0.05% 
Tween, 150 μl of detection antibody was added. Plates were read using the MS2400 
imager (MSD).  
The lowest limit of quantification (LLOQ) was defined as the lowest calibrator value 
at which the coefficient of variance of concentration was less than 30% and recovery of 
calibrator was within 30% of the expected value (as suggested by the manufacturer). All 
cytokine values that were below the LLOQ were considered undetectable and assigned 
a value equal to the plate-specific LLOQ for statistical analyses.  
 
Statistical Analyses 
To determine differences in proportions and means, the Fischer’s exact chi square 
and the t test statistic were used, respectively. The Wilcoxon rank sign test was used to 
compare median cytokine levels of TIV and LAIV users at day 0; the paired test was 
used to compare the median levels of each cytokine at day 0 to day 14 and day 28. A 
serologic response to vaccine was defined as a ≥4-fold increase in titers compared to 
day 0.  A two-sided p-value of <0.05 guided statistical interpretation.  All analyses were 






2.4.1 Study population 
A total of 42 and 58 volunteers were recruited and enrolled in the 2006-07 and 2007-
08 influenza seasons, respectively. Nine individuals from the first year also participated 
in the second year of the study. Demographic characteristics of LAIV and TIV recipients 
were similar in the 2006-07 influenza season (Table 2.1).  In the 2007-08 season, a 
higher proportion of men received LAIV than TIV (62% vs. 32%, p=0.05), and greater 
number of individuals who had never been previously vaccinated received LAIV 
compared to TIV (38% vs. 6%, p<0.01; Table 2.1). Due to a delay in the availability of 
LAIV in the 2007-08 season, LAIV recipients were recruited slightly later (November 
















Table 2.1:  Characteristics of study participants at baseline, by influenza season 
and vaccination type 
 
‡Medications excluding birth control. 
†p-values for differences in proportions calculated using Fischer's exact chi square test statistic; p-values for 
differences in means calculated using a t test statistic.  Note: Due to n=10 subjects contributing to both 




2.4.2 Serum antibody responses to seasonal vaccination 
Induction of serum antibody responses is the current gold standard for evaluating 
influenza vaccines (175). Therefore, we first examined the serum antibody response to 
seasonal TIV and LAIV using the standard hemagglutination inhibition assay (HI). As 
shown in Fig 2.1a, TIV induced a significant increase in antibody titers at day 14 and day 
28 post-vaccination during the 2006-07 and the 2007-08 influenza seasons. In contrast, 
the serum antibody response to LAIV was substantially lower than that of TIV (Fig 2.1b). 
As shown in Table 2.2, the sero-response rate, defined as the percentage of vaccine 




Guidances/Vaccines/ucm074794.htm) at day 14 and day 28 post-vaccination was 
significantly greater in recipients of TIV compared to LAIV. No statistically significant 
differences were observed in the sero-response rates between male and female 
participants (data not shown). These data are in agreement with previous studies 
(162,176) suggesting that the vaccines used in this study induced antibody responses 




































Fig 2.1. Serum antibody titers against influenza vaccine strains were determined by standard 
hemagglutination inhibition assay (HI). Antibody titers were determined prior to vaccination (day 
0) and again at day 14 and day 28 post-vaccination with (a) TIV and (b) LAIV during the 2006-07 
as well as the 2007-08 season. *p<0.05, student t test. 
 
Table 2.2:  Sero-response† rates at day 14 and day 28 by season, vaccine type and 
vaccine strain 
 
†Sero-response is defined as a >4- fold increase in titers from day 0. ‡P-value determined using Fischer’s 
exact chi square test statistic. 
 
2.4.3 Serum cytokine response to seasonal vaccination 
To determine the effect of vaccination type on serum cytokines, we quantified the 
levels of 10 cytokines (IFN-γ, IL-1β, IL-2, IL-4, IL-5, TNF-α, IL-8, IL-12p70, IL-13 and IL-
10) in the serum of volunteers before (day 0) and at 14 and 28 days after vaccination 
with either TIV or LAIV. As expected, the cytokine values were not normally distributed, 
so we examined medians (instead of means) in our statistical analyses. Of the 10 
cytokines measured, only IL-10, IL-8 and TNF-α were reliably detectable in at least 70% 
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of our cohort at all three time points (days 0, 14 and 28 post-vaccination). Due to the 
difficulty in interpreting data with a large number of undetectable values, we restricted 
further statistical analyses to these three cytokines. 
Despite small difference in the demographics between the 2006-07 and 2007-08 
seasons, when we compared the median values of the three cytokines at day 0, we 
found no differences between the 2006-07 and 2007-08 seasons (Table 2.3). Thus we 
combined the data by vaccine type over the two seasons. Surprisingly, among TIV 
recipients, the levels of IL-8 decreased by 40% (p<0.01) at day 14 and 33% (p<0.01) at 
day 28 compared to levels at day 0 (Fig 2.2). Similarly, TNF- levels also decreased 
significantly at days 14 and 28, albeit to a lesser extent (13% and 9% at days 14 and 28, 
respectively, p<0.05) (Fig 2.2). This effect was not observed in those vaccinated with 
LAIV (data not shown).  The levels of IL-10 remained unchanged from baseline levels at 
both 14 and 28 days post vaccination regardless of the vaccine type (TIV: 2.05 pg/ml at 
day 0 compared to 2.0 pg/ml and 2.09 pg/ml at days 14 and 28, respectively, p>0.05. 

























‡ Undetectable results were assigned a value equal to the lower limit of detection and included in 
the median calculations. † p-values for the differences in medians comparing 2006-07 and 2007-
08 seasons were calculated using the Wilcoxon signed rank test 
 








Fig 2.2. Serum cytokines were measured in serum of vaccine recipients prior to vaccination (Day 
0) and at days 14 and 28 days post-vaccination.  * p <0.05, Wilcoxon rank sign test of medians 









2.4.4 Correlation between serum cytokine profiles and antibody responses 
We next determined if the changes in IL-8 and TNF-α concentrations after 
vaccination correlated to “vaccine take” as measured by sero-response (175). However, 
no significant correlation could be found between sero-response at day 14 and day 28 
and cytokine changes in TIV recipients in our cohort (data not shown).  
Finally, to determine if baseline cytokine levels can predict sero-response, we 
compared median values of serum cytokines at day 0 between sero-responders and 
non-responders. Due to the poor sero-response rate in LAIV recipients (Table 2.3), we 
restricted our analysis to TIV recipients. There was a borderline statistically significant 
difference in the median baseline levels of IL-8 between sero-responders and non-
responders (to any of the three influenza strains) at day 14 (Table 2.4). The median 
value of IL-8 was higher for sero-responders compared to non-responders (13.89pg/ml 
compared to 9.01pg/ml, p=0.05). 
 
Table 2.4: Comparison of median cytokine levels at day 0 among sero-responders 
and non-responders in TIV recipients (2006-07 and 2007-08 season participants 








†Sero-response against any of the three vaccine strains.  Sero-response is a ≥4-fold increase in 
titers from day 0 to day 14. ‡p-value comparing median cytokine value between responders and 





Vaccination remains one of the most effective means to control the spread of 
infectious diseases (177). However, little is known about the immunologic mechanisms 
which underlie effective vaccine strategies.  In designing new vaccines against influenza 
as well as other infectious diseases such as malaria and HIV, understanding host factors 
that shape the development of protective immunity are key (178,179). Changes in 
cytokine profiles after infection have often provided important insight into the 
mechanisms mediating protective immunity to re-infection (167,168). Therefore, in this 
study, we sought to determine if serum cytokines could be used as a tool to better 
understand the immune response to seasonal influenza vaccination.  
Serum anti-HA titers, measured by the hemagglutination inhibition assay (HI titers) 
are the gold standard for measuring influenza vaccine efficacy and, a greater than 4-fold 
increase in serum anti-HA  titers is deemed a sero-response (157,175). Several factors 
have been shown to affect the sero-response rates in vaccine recipients including 
presence of circulating antibodies at the time of vaccination (176). Previous studies 
indicate that in individuals with pre-existing antibodies, the humoral response to TIV and 
LAIV is significantly lower than in individuals without pre-existing antibodies 
(164,176,180,181). Since we did not pre-select study participants based on sero-
negativity to vaccine strains we found that the majority (>90%) of vaccine recipients had 
pre-existing antibodies at baseline to all of the vaccine strains included in both season’s 
vaccines as shown in Table 2.1 (individuals with an HI titer of > 8 were deemed sero-
positive as previously reported (180)). The lower sero-response rates reported in this 
study are consistent with sero-response rates reported in other seasonal influenza 
vaccine studies in healthy volunteers who were not pre-selected based on sero-
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negativity to vaccine strains (162,181,182). One could speculate that circulating anti-HA 
antibodies at the time of vaccination could form complexes with HA in the vaccines, 
thereby reducing the amount of antigen available for stimulating naïve and/or memory B 
cells, thereby impacting the serum antibody response. In support of this hypothesis, 
Sasaki S, et al., demonstrated an inverse relationship between circulating anti-HA 
antibodies and peripheral effector B cell responses, at least to TIV (176). It would be 
interesting in future studies to determine if the presence of pre-existing antibodies 
negatively correlates with vaccine effectiveness.  
In thus study we detected a substantially higher sero-response rate in recipients of 
TIV compared to LAIV corroborating findings from other studies (183,184). Despite the 
poor sero-response rates in LAIV recipients, both vaccines have been shown to be 
equally efficacious in preventing infection against homologous strains of virus (183-185) 
. This raises the possibility that immune mechanisms, other than serum antibodies, may 
contribute to protection, especially after vaccination with LAIV.  In line with this, studies 
have shown that, in addition to serum IgG antibodies, induction of mucosal IgA 
antibodies also correlate with protection against influenza infection (163,186).  
Importantly, it has been shown that LAIV induces an increase in such mucosal IgA 
antibodies in vaccine recipients (164,182). In fact, such mucosal responses were more 
frequent in recipients of LAIV than TIV, suggesting that the two vaccines may stimulate 
different antibody compartments (185). In addition, the impact of either seasonal vaccine 
on other immunological parameters such as T cell responses are not well understood 
and warrant further study. This will be the focus of the next chapter of this thesis. 
Previous studies characterizing cytokine changes following vaccination have typically 
focused on early time points immediately following vaccination during innate recognition 
(187). While rapid changes in cytokines can provide important clues regarding the 
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activation of different innate cell subsets, their correlation with adaptive immunity is not 
clear. Studies in mice suggest that the levels of cytokines at the peak of the adaptive 
immune response (typically between days 7-14 post infection) correlate with the type of 
T helper and B cell response to influenza vaccination (188,189).  Accordingly, in this 
study, we examined the sustained cytokine levels at the peak of the adaptive immune 
response to gain insight into mechanisms of adaptive immunity. We found that 
immunization with TIV, but not LAIV, was associated with a significant decrease in the 
serum levels of IL-8 and TNF-at 14 and 28 days post-vaccination. IL-8 and TNF-are 
potent pro-inflammatory mediators that contribute to host protection against influenza as 
well as other infectious pathogens (190-192). During the early stages of the immune 
response to pathogens including influenza, TNF- (Y. Chen and J. Bream, manuscript 
in preparation) and IL-8 are actively secreted by innate mononuclear cells as well as 
endothelial cells (193). IL-8 in particular, serves as an important chemoattractant and 
recruits other inflammatory cells including neutrophils and T cells to the site of 
infection/vaccination (194). The decrease in the serum levels of IL-8 and TNF-at later 
time points after vaccination could reflect cytokine uptake or redistribution of immune 
cells to other compartments. Interestingly, a similar decrease in other soluble mediators 
of inflammation including MIP-1MIP-1and IFN- was observed during the acute 
phase of seasonal and pandemic influenza infections (195). 
In contrast to TIV, we observed no significant changes in cytokines at either time-
point after vaccination with LAIV. Since LAIV is administered through an intranasal route, 
it is possible that, like antibodies (183,196), cytokine responses may also be contained 
within the local mucosa and not readily detectable in the periphery. This idea is in 
agreement with previous studies that reported changes in cytokine profiles in nasal wash 
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but not serum of animals and humans infected or vaccinated with influenza and RSV 
(197-199). Measuring nasal wash cytokines may, therefore, be more instructive in 
understanding mechanisms of immune activation following administration of LAIV and 
other mucosally-delivered vaccines.  Alternatively, and as previously reported, it is 
possible that the kinetics of the cytokine response differs in TIV and LAIV recipients and 
that our study missed the peak in the peripheral cytokine response after LAIV 
administration (199).  
Using a systems biology approach, other groups have shown that early immune 
signatures can predict adaptive responses to immunization, including seasonal influenza 
vaccination (187,200). Identifying early markers of immunogenicity might help in early 
identification of non-responders, which could prove valuable from a public health 
standpoint. We found that sero-responders to TIV had modestly higher baseline levels of 
IL-8 compared to non-responders (p=0.05, Table 5). Consistent with this finding, several 
other groups also reported higher baseline levels of IL-8 in patients who respond better 
to BCG vaccination in the prevention of recurrence of bladder tumors (201,202). 
However, given the weak association between baseline levels of IL-8 and sero-response 
in our cohort, it is too soon to speculate on the significance of this finding.  
There are some caveats to this study that should be noted.  Firstly, the sample size 
is relatively small and consisted only of healthy adults.  Thus, age or smaller effects may 
have been missed.  In addition, the small, but consistent, absolute change in IL-8 and 
TNF- levels after TIV draws into question the biological meaning of small shifts in 
cytokine amounts.  While the biological significance of such small changes has yet to be 
determined, another study has shown that even small doses of recombinant cytokines 
and chemokines, administered in vivo, can impact signaling pathways in peripheral cells 
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(203).  Finally, changes in serum cytokines/ chemokines that may have occurred 
immediately following vaccination with either TIV or LAIV were likely missed in this study 
and warrant further study.   
In conclusion, in this study we report for the first time that the killed, parenteral (TIV) 
but not a live, mucosal (LAIV) seasonal influenza vaccine has the capacity to alter the 
balance of peripheral cytokines up to 4 weeks post-vaccination. This study serves as a 
proof of principle that serum cytokine changes following seasonal influenza vaccination 
can be detected. Their significance with respective to the induction of protective 
immunity warrants further investigation. Our data also suggest that baseline IL-8 levels 
may impact the development of the adaptive immune response to TIV. It will be 
important for future studies to determine how changes in cytokine profiles may relate to 
changes in immune cell activation to provide another tool to dissect the cellular and 
molecular mechanisms of vaccine-induced immunity. Furthermore, such studies could 
prove valuable in understanding host factors which regulate the immune response to 






CHAPTER 3: Heterotypic T cell responses to seasonal 
influenza vaccination in humans 
 
3.1 Abstract 
Mounting evidence suggests that seasonal influenza vaccines may not be as efficacious 
as once thought which underscores the need to better understand vaccine-induced 
immunity. Although antibodies provide influenza strain-specific protection against 
infection, the role of cell mediated immune responses in host defense against influenza 
are being increasingly recognized.  This is of particular importance considering the 
ongoing threat of emerging pandemic influenza strains. Using a cohort of vaccinees from 
the 2006-07 season we examined the capacity of the trivalent influenza vaccine (TIV) 
and the live attenuated influenza vaccine (LAIV) to induce homologous and heterologous 
T cell responses.  We used a combination of circulating and novel influenza viruses and 
select peptide pools to assess influenza-specific T cell responses. We found that prior to 
vaccination, CD4+ and CD8+ T cells, unlike antibodies, were broadly cross-reactive to 
whole, heterotypic influenza A viruses. Interestingly, vaccination with TIV and LAIV, 
induced significant increases in the frequency of homotypic and heterosubtypic 
influenza-specific CD4+ T cells. This increase in total T cell frequency was also 
accompanied by a change in T cell quality, at least in recipients of TIV. Further studies 
are required to determine if these changes in total T cell magnitude and/or quality 
against seasonal and newly emergent influenza strains after vaccination will serve to 






Influenza is a respiratory pathogen that continues to pose a significant public health 
risk resulting in 3 to 5 million cases of severe disease worldwide every year (World 
Health Organization WHO factsheet 211:influenza; 2003) and between 17,000-51,000 
deaths in the United States every year (3). In addition to seasonal epidemics, newly 
emerging influenza strains (such as H5N1 and H7N9) remain a serious threat to global 
public health. With an estimated mortality rate of 70% and 30% for H5N1 and H7N9 
infections, respectively (204), the spread of such highly pathogenic strains in the human 
population could have catastrophic effects on human health and world economy. 
Vaccination remains the most effective means to reduce the disease burden and 
economic impact of influenza (205).  In the United States there are two types of 
approved seasonal influenza vaccines: the Trivalent Inactivated Influenza Vaccine (TIV) 
and the Live Attenuated Influenza Vaccine (LAIV). Influenza vaccines are generally 
thought to confer protection by the induction of antibodies against the two major surface 
proteins, namely Hemagglutinin (HA) and Neuraminidase (NA) (206). Due to continual 
antigenic drift in HA and NA, the seasonal vaccines are reformulated every year to 
match circulating strains. When the vaccine and circulating strains are well matched, the 
seasonal vaccines were previously thought to be between 90-100% effective against 
seasonal infections (130,139). However, their true effectiveness has recently been 
debated with many studies reporting effectiveness of only 50% in healthy adults and as 
low as 6% in vulnerable population such as young children and the elderly, even during 
years of good antigenic match (123,142). In years of mismatch or in the event of an 
emergence of a new pandemic, as in 2009, the efficacy of the current vaccines in 
preventing infection is thought to be even lower (207,208). In addition, recent studies 
have reported a decline in antibody levels just one month after vaccination resulting in a 
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reduction in vaccine effectiveness over time (209). Taken together, these data highlight 
some major limitations and drawbacks in the current vaccines and underscore the need 
for more effective strategies. 
To this end, there has been a substantial increase in vaccine discovery and 
development efforts, as outlined in section 1.3.5 (206). The development of more 
effective vaccines that can induce long lived immunological memory across various 
influenza subtypes, or the so-called “universal” influenza vaccine is critical to controlling 
disease burden. However, the rational design and development of such new vaccines 
has been slow and challenging, in part because little is understood about the 
immunological underpinnings of successful vaccination (210). In fact, LAIV still has no 
accepted correlate of protection.  
The vast majority of past work has focused on the ability of influenza vaccines to 
induce strain-specific serum anti-HA antibodies (175) with little regard to mechanisms 
that drive optimum antibody production or cross-reactive immunity (162,164). An 
accumulating body of evidence suggests that T cells may contribute to both of these 
processes. Unlike B cells, T cell recognition of influenza is not restricted to surface 
proteins and instead can mount responses to the internal proteins, which are highly 
conserved across different influenza strains (80,211,212). Accordingly memory T cells 
established by seasonal infections have been shown to recognize novel influenza 
viruses and are thought to be important mediators of heterosubtypic immunity, at least in 
animal models. In humans, this idea has only recently been reinforced by studies which 
identify a direct link between memory T cells and protection from severe disease. For 
instance, experimental challenge with influenza demonstrated that pre-existing memory 
CD4 T cells (induced either through vaccination or natural infection) could mediate viral 
clearance and recovery from infection, even in the absence of detectable serum 
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antibodies (78). Similarly, another study of over 300 individuals showed that pre-existing 
memory CD8 T cells were able to protect from severe disease during the 2009 pandemic 
(81). Thus T cells may be able to provide partial protection against novel influenza 
viruses. In addition to contributing to direct clearance of infected cells, T cell responses 
have also been shown to be crucial for the induction and maintenance of long-lived B 
cell memory and high affinity antibody production (67,68,213), which is of course of great 
interest from a vaccination standpoint.  
The commercially available influenza vaccines offer a platform to study the 
development of T effector as well as memory responses in humans. The seasonal 
influenza vaccines are additionally unique because they also allow for comparisons of 
different routes of immunization and/or vaccine formulations on T cell immunity. This 
information could be invaluable in guiding future vaccination strategies not just against 
influenza but also other pathogens for which induction of T cell immunity is likely to be 
important, such as HIV or tuberculosis (206,210).  A major hurdle in the assessment of T 
cell responses is that currently there are no accepted standard assays (210,214).   The 
added complexity of T cell heterogeneity based on functional (ability to secrete multiple 
effector molecules including IFN-γ, TNF-α and IL-2) and memory phenotype (based on 
expression of tissue homing markers into central memory and effector memory) further 
confounds this issue (215,216).  Variations in cell and reagent handling, stimulation 
protocols and functional and phenotypic measurements has made cross-study 
comparisons impossible. The capacity of influenza vaccines to induce T cell responses 
has been somewhat contentious, in large part due to this variability (182,217-220). In 
this study, we developed a novel flow cytometry-based lyophilized antibody/antigen 
platform for the high-throughput characterization of influenza-specific T cells. We then 
used this platform to address the capacity of the two seasonal influenza vaccines (TIV 
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and LAIV) to induce homotypic CD4 and CD8 T cell responses against strains contained 
in the vaccine as well heterotypic T cells responses to divergent strains including the 





Study design and human subjects 
Forty two participants between the ages of 18 and 49 were recruited in the fall of the 
2006-07 influenza season between October and November.  Participants were screened 
by questionnaire at each visit to assess health history including recent acute illness. 
Volunteers were excluded from the study if they reported to be immuno-compromised 
due to chronic illness or medication and there were no reports of recent acute illness 
during the study visits. All volunteers provided written informed consent and choose their 
vaccine type: LAIV (Flumist, Medimmune) or TIV (Fluzone, Aventis Pasteur). A total of 
17 participants received LAIV and another 25 received TIV, of whom 17 were randomly 
selected to be included in this study. Immediately prior to vaccination (day 0), a venous 
blood specimen of approximately 50 ml was collected. Volunteers were then immunized 
following current guidelines for influenza vaccination.  Participants provided additional 
blood samples at 14 (day 14) and 28 days (day 28) after vaccination. Serum was 
harvested from blood samples using serum separator tubes (BD Bioscience, San Jose, 
CA) and stored at -80˚C. The 2006-07 seasonal vaccines contained A/New 
Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004. 
 
PBMC isolation and cryopreservation 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using 
Ficoll-Paque density gradient centrifugation. Briefly, whole blood gently layered on top of 
Ficoll-Paque in a 50ml conical tube. Cells were then centrifuged at 2400rpm for 20 
minutes at room temperature with brake. After centrifugation, the interface containing 
mononuclear cells was carefully transferred using a 10ml pipette to a new conical tube. 
Transferred mononuclear cells were diluted in distilled phosphate buffered saline 
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(DPBS) and centrifuged twice at 1500rpm for 15 minutes at room temperature. Washed 
PBMCs were frozen at a concentration of 1x107/ml in freezing media (20%FBS+80% 
RPMI with penicillin and streptomycin) 
 
Influenza viruses, peptides and antibodies 
Influenza viral strains used in this study: A/Wisconsin/67/2005 (H3N2), A/New 
Caledonia/20/1999 (vH1N1), A/Solomon Islands/3/2006 (sH1N1), A/California/04/2009 
(pH1N1) and B/Malaysia/2506/2004 (Flu B), were obtained from the CDC. The negative-
sense RNA virus vesicular stomatitis virus (VSV) was kindly provided by Dr. Andrew 
Pekosz from the Johns Hopkins School of Public Health and was used as a negative 
control. All viruses were propagated in Madin-Darby canine kidney (MDCK) cells and 
purified using a 20% sucrose cushion. Viruses were then inactivated using 0.05% β-
propiolactone (BPL) treatment overnight at 4˚C. Samples were then heated at 37˚C for 2 
hours to inactivate the compound. Virus inactivation was confirmed by the lack of 
cytopathic effects (CPE) on MDCK cells. 
Individual peptides from influenza proteins HA (NR-9472), M1 (NR-2613), NP (NR-
2611) and PB1 (NR-2617) were obtained from the NIH Biodefense and Emerging 
Infections Research Repository, NIAID, NIH. Peptides were suspended in DMSO and 
pooled to generate peptide pools for each protein. Peptides were 13- to 17-mers with 7 
to 12 amino acid overlaps. The HA, M1, NP and PB1 pools consisted of 94, 41, 82 and 
126 peptides respectively. Staphylococcal enterotoxin B (S4881, Sigma Aldrich) was 






Hemagglutination inhibition assay (HI) 
HI titers were measured in serum samples for all three vaccine strains in each 
season as described in the previous chapter. Influenza virus strains A/New 
Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), B/Malaysia/2506/2004 and A/ 
Solomon Islands/3/2006 (H1N1) were obtained from the CDC.  Serum samples were 
pretreated with receptor destroying enzyme (Lonza Inc., Walkersville, MD) overnight at 
37˚C. Samples were then treated with Sodium Citrate (1.6%) and heated at 56˚C for 45 
minutes. The hemagglutination inhibition (HI) assay was performed as described 
previously (183).  Briefly, 25 μl of specific influenza virus (4 HA units) was added to 25 μl 
of serum serially diluted in 2-fold dilutions till 1:2048 in PBS and incubated for 1 hour at 
room temperature. 50 μl of 0.5% chicken red blood cells (for influenza A/ H1N1 and 
influenza B) and 0.5% turkey red blood cells (for influenza A/ H3N2 and A/ pH1N1) was 
then added and incubated for a minimum of 30 minutes before reading the HI activity. All 
erythrocytes were obtained from CBT farms (city, state). The HI antibody titer for a given 
sample was defined as the reciprocal of the last dilution at which there was complete 
inhibition of HA activity. A titer of 2 was assigned to all samples in which the first dilution 
(1:4) was negative.  
 
Lyophilized reagent plates for stimulation and staining  
Stimulation plates were formulated with individual peptide pools at a concentration of 
1.7 µg/peptide and Brefeldin A (BFA) at a concentration of 10 µg/ml or purified 
inactivated viruses (Multiplicity of infection =1) without BFA and then lyophilized into 
poly-propylene V-bottom 96-well plates. Similarly, staining plates were formulated with 
appropriate antibody mixtures in appropriate wells and lyophilized. Two antibody 
mixtures were used: The surface staining cocktail consisted of:  CD3-APC-H7, CD4-
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PerCPCy5.5, CD8-V500, CCR7-PE, CD45RA-PECy7 and CD28-APC. The intracellular 
staining cocktail consisted of IFN- -V450, IL-2-FITC and TNF--Alexa 700. All 
antibodies were obtained from BD Biosciences. 
 
Stimulation for intracellular cytokine assays 
Cryopreserved PBMCs were thawed and rested for four hours at 37ºC. Rested cells 
were added to each well of the lyophilized stimulation plates containing peptide pools or 
whole inactivated viruses at a concentration of 5x106 cells/ml and mixed well with 
micropipetter to reconstitute the lyophilized pellet in a total volume of 100 µl. Control 
media containing BFA was used for background subtraction. For peptide stimulations, 
cells were stimulated for 6 hours at 37°C and then transferred to staining plates. For 
whole virus stimulations, PBMCs were added to wells containing whole virus in 100 µl of 
incomplete media lacking FBS. Cells were incubated for 1 hour at 37°C and then 
reconstituted with 10% FBS. Cells were then incubated for another 17 hours and BFA 
was added for the last 6 hours, following which the cells were transferred to staining 
plates. 
 
Staining for intracellular cytokine assays 
Stimulated cells were washed twice in 1x PBS and then stained with LIVE/DEAD 
fixable stain (Invitrogen, L34959) as per manufacturer’s instructions. Surface and 
intracellular staining was then performed on cells as described previously with minor 
modifications (221). Briefly, staining plates containing the surface staining cocktail were 
hydrated in wash buffer (PBS +0.5% BSA) and then added to the stimulated cells. Plates 
were incubated at room temperature for 30 minutes and then washed once. Cells were 
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then incubated with FACS lysing solution (BD Biosciences) for 15 minutes at room 
temperature. Plates were then frozen at -80°C before further processing. Frozen plates 
were thawed at 37°C and washed once in wash buffer. Permeabilizing Solution 2 (BD 
Biosciences) was then added and plates were incubated for 10 minutes at room 
temperature. Plates were washed twice in wash buffer and finally the rehydrated 
intracellular staining antibodies were added and incubated for 1 hour at room 
temperature. Plates were then washed twice, suspended in 1x PBS and then acquired 
on a BD LSR II flow cytometer and analyzed using FlowJo (Tree Star).  
   
Statistical analysis 
Baseline comparisons of T cell and antibody responses between viruses were tested 
using the Kruskal-Wallis test. Changes in cytokine secreting CD4 and CD8 T cell 
frequencies pre- and post-vaccination were tested using Wilcoxon signed rank test. 






3.4.1 Assay optimization and lyoplate generation 
Reagent lyophilization can potentially allow for the standardization of reagent 
handling and protocols across multiple laboratories (223-225). However, lyophilized 
reagent plates (henceforth referred to as lyoplate) have not previously been used for 
whole virus stimulations. Therefore, we first optimized the conditions for CD4 and CD8 T 
cell stimulation using whole inactivated viruses. We tested three different methods of 
virus inactivation namely, β-propiolactone, heat inactivation at 56ºC and UV inactivation. 
We found that stimulation of T cells with virus inactivated with β-propiolactone was 
closest to live virus stimulations in terms of IFN-γ and IL-2 production (data not shown). 
In addition, virus inactivation was most consistent using β-propiolactone. Therefore all 
viruses were inactivated with β-propiolactone in this study. Other parameters tested 
included concentrations of virus and durations of stimulation (data not shown).  
To ensure that lyophilization of antigen and/or antibody did not affect T cell 
stimulation or staining, the standard soluble assay was carried out side-by-side with 
lyophilized reagent plates. Fig 3.1 shows representative pre-vaccination samples 
stimulated with A/New Caledonia/20/1999 ex vivo either via the standard soluble assay 
or via lyophilized reagents (hereby referred to as lyoplate). The two assays were highly 
comparable in terms of staining as well as stimulation as evidenced by the percentage of 
cytokine producing CD4 (Fig 3.1a) and CD8 T cells (Fig 3.1b). Data represented in the 






Figure 3.1  Comparison of soluble and lyophilized platforms 
a.                                                                             b. 
 
Fig 3.1. PBMCs were stimulated and stained using soluble reagents or pre-configured lyophilized reagents 
(lyoplates). Representative plots from a pre-vaccination sample stimulated with A/New Caledonia is shown 
for CD4 (a) and CD8 (b) T cells stained for IFN-γ, TNF-α and IL-2. 
 
3.4.2 Cross-reactivity of influenza-specific antibodies prior to vaccination 
Serum antibodies are an established correlate of protection against influenza and the 
gold standard for vaccine effectiveness (at least for TIV) (85). Therefore, we first 
examined the extent of antibody cross-reactivity to circulating and novel influenza strains 
by measuring anti-HA antibodies in the serum of vaccine recipients prior to seasonal 
vaccination. Consistent with previous exposure, all participants had detectable anti- HA 
antibodies (HI titer>8 as indicated by the dashed line, Fig 3.2) against strains that were 
in circulation prior and during sample collection (A/New Caledonia/20/1999- vH1N1, 
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A/Wisconsin/67/2005- H3N2 and B/Malaysia/2506/2004- Flu B)(226). In addition, we 
measured antibody titers against an antigenic variant of A/New Caledonia/20/99, namely 
A/Solomon Islands/3/2006-sH1N1, which had widespread activity in the United States 
only during the 2007-8 season(227), and the 2009 pandemic H1N1 
(A/California/4/2009)-pH1N1. While the circulating strain (vH1N1) and seasonal drift 
variant (sH1N1) share 98% sequence identity in the HA protein, antibody titers against 
sH1N1 were significantly lower than vH1N1 (HI titer of 128 against vH1N1 compared to 
32 against sH1N1, p<0.001). These data suggest poor conservation in the antibody 
binding epitopes in HA, even between closely related strains. Not surprisingly, titers 
against the pandemic H1N1 strain (pH1N1), which only shares 75% sequence identity 
with the circulating H1N1 HA, were the lowest amongst all influenza strains tested (HI 
titer of 16). 
 
Figure 3.2  Baseline (day 0) antibody titers against influenza strains 
 
Fig 3.2. Serum anti-HA antibody titers 
to various influenza strains prior to 
vaccination was determined using the 
hemagglutination inhibition assay (HI) 
(TIV and LAIV groups were combined 
at baseline; N=42). The dashed line 
indicates seronegativity (HI<8).  







3.4.3 Cross-reactivity of influenza-specific T cells prior to vaccination 
Next, we examined the extent of T cell cross-reactivity against the same influenza 
strains. Cryopreserved PBMCs were stimulated with lyophilized whole, -propiolactone 
inactivated influenza virus and the frequency of total cytokine (IFN-γ, IL-2 or TNF-α or 
any combination of the three) producing CD4 and CD8 T cells was evaluated as 
described below. A gating tree from a representative pre-vaccination sample stimulated 
ex vivo with A/New Caledonia/20/1999 is shown in Fig 3.3. As described previously 
(170), within the gated CD4+ and CD8+ T cell population, cells were separated into IFN-
γ+ and IFN-γ- cells and further assessed for the production of IL-2, TNF-α or both. This 
analysis revealed 7 functionally distinct populations of cells that make IFN-γ, IL-2, TNF-α 
or any combination of the three. Together, these seven populations comprise the 
frequency of total cytokine producing CD4 or CD8 T cells.  
Similar to antibodies, most individuals (>95%) had detectable levels of CD4 (Fig 
3.4a) and CD8 T (Fig 3.4b) cells against strains that were in circulation prior to sample 
collection (A/New Caledonia/20/1999-vH1N1, A/Wisconsin/67/2005-H3N2 and 
B/Malaysia/2506/2004-Flu B). However, in contrast to antibody titers, we detected 
significant CD4 and CD8 T cell cross-reactivity to antigenic variants, namely A/Solomon 
Islands/3/2006-sH1N1 and A/California/4/2009-pH1N1. As shown, CD4 and CD8 T cells 
against sH1N1 and pH1N1 were detected in the majority (>95%) of our participants prior 
to vaccination. In fact, the frequency of CD4 and CD8 T cells against pH1N1 and sH1N1 
was comparable to that against the circulating H1N1 strain (vH1N1)(p>0.05) and was 
higher than those against other circulating influenza strains (A/Wisconsin/67/2005-H3N2 
and B/Malaysia/2506/2004-FluB).    
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While antibodies against influenza are predominantly directed against hemagglutinin 
(HA), we were able to detect CD4 and CD8 T cells against several internal proteins, with 
the highest frequency of CD4 and CD8 T cells directed against NP (Fig 3.4c and d). The 
ability of CD4 and CD8 T cells to recognize invariant epitopes derived from highly 
conserved internal proteins (75) is likely responsible for the high degree of cross-
reactivity to antigenic variants observed in this and other studies (211).  
 
Figure 3.3  Gating tree for functional characterization of influenza specific T cells 
 
Fig 3.3. The gating strategy 
is shown for a 
representative pre-
vaccination samples 
stimulated ex vivo with 
influenza strain A/New 
Caledonia/20/1999.  Based 
on the expression of IFN-γ, 
TNF-α and IL-2, seven 
distinct functional 
populations of cytokine 
producing cells can be 
ascertained (numbered 1-7 
in Fig 3.3). These seven 
populations together 
comprise the total cytokine 
producing population of 











 Figure 3.4  Baseline (day 0) T cell responses to influenza viruses 
a. b.                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
c.                                                         d. 
 
Fig 3.4. PBMCs were stimulated ex vivo with whole, β-propiolactone inactivated influenza viruses and 
vesicular stomatitis virus (VSV) as negative control. Frequency of virus-specific CD4+ (a) and CD8+ (b) T 
cells (comprising of IFN-γ, TNF-α, IL-2 or any combination of the three cytokines) was determined by 
multicolor flow cytometry. Additionally, PBMCs were also stimulated with individual peptide pools derived 
from influenza proteins and the frequency of antigen specific CD4+ (c) and CD8+ (d) T cells (comprising of 
IFN-γ, TNF-α, IL-2 or any combination of the three cytokines) was determined.  Individual values are shown 





3.4.4 Functional and phenotypic characterization of influenza-specific T cells 
After evaluating the total CD4 and CD8 T cell response to influenza in unvaccinated 
adults, we then evaluated the “quality” of the response as determined by the co-
expression of IFN-γ, TNF-α and IL-2 (215). The quality of the T cell response refers to 
the functional capacity of T cells (in terms of cytokine secretion, expression of cytolytic 
markers, etc). T cells that can simultaneously express multiple effector functions have 
been previously shown to correlate with improved protection after vaccination and are 
therefore considered to have a better quality (59,228-231).  To determine the “quality” of 
the CD4 and CD8 T cell response, we combined the 7 cytokine producing populations 
described above into 3 functional categories based on the number of cytokines that are 
simultaneously expressed (any one, any two and all three) (215). As shown in Fig 3.5a 
and b, virus-specific cytokine expression patterns in CD4 T cells were heterogeneous 
and consisted of single, double and triple cytokine producing populations. CD4 T cells 
making any one cytokine (IFN-γ, IL-2 or TNF-α) constituted approximately 40-50% of the 
total cytokine producing CD4 T cell population against influenza while double and triple 
producers accounted for 30% and 20% of the response respectively (Fig 5a).  
Interestingly, the CD4 T cell cytokine response against pH1N1 showed the least 
heterogeneity with close to 70% of cells making only one cytokine. In contrast, CD8 T 
cell responses against all viruses were largely restricted to single cytokine producers 
(accounting for approximately 70% of the total response) (Fig 3.5c and d). Once again, 
the CD8 T cell response to pH1N1 was more restrictive in terms of their cytokine 
secretion profiles with over 90% of the total CD8 T cell response to pH1N1 comprised of 
single cytokine producers compared to 70% against seasonal H1N1 viruses (Fig 3.5c). 
In addition to qualitative differences, CD4 and CD8 T cells also possess distinct 
phenotypic profiles that maybe predictive of protective efficacy. A well-established model 
65 
 
of classification is based on the expression of CD45RA and CCR7 (216,232,233). Based 
on the expression of these surface markers, CD4 and CD8 T cells can be divided into 
naïve-like (CD45RA+CCR7+),  central memory TCM (CD45RA-CCR7+), effector memory 
TEM (CD45RA-CCR7-) and terminal effector TTE (CD45RA+CCR7-) populations. To 
determine the phenotype of cytokine producing cells, we included only those samples 
with > 30 cytokine+ events and cytokine+ frequencies >3x over background (222). 
CD45RA and CCR7 gates were set on total CD4 and CD8 T cells (Fig 3.6a) and then 
applied to cytokine+ CD4 and CD8 T cell populations. As shown in Fig 3.6b cytokine+ 
CD4 T cells against seasonal influenza strains were predominantly effector memory 
(TEM) and central memory (TCM) cells, constituting approximately 40% and 30% of the 
total response, respectively. Terminally differentiation effectors (TTE) accounted for a 
small percentage of the total response (roughly 10%). Interestingly, a sizeable proportion 
of cytokine+ CD4 T cells (20%) were found to have a naïve-like phenotype. Similarly, 
cytokine+ CD8 T cells were predominantly TEM (40%-50%) (Fig 3.6c). However, greater 
variability in surface phenotype in CD8 T cells against the different viruses was noted. 
 
 Figure 3.5  Quality of influenza-specific T cells at baseline (day 0) 




c.                                                          d. 
 
Fig 3.5.  (a) The relative proportion of cells within total cytokine producing CD4+ T cells that make any one 
(IFN-γ, TNF-α or IL-2), a combination of any two and all three cytokines was determined for each virus. 
(b)The frequency of CD4+ T cells that are single (      ), double (      ) or triple cytokine (      ) positive.  (c) The 
relative proportion of cells within total cytokine producing CD8+ T cells that make any one (IFN-γ, TNF-α or 
IL-2), a combination of any two and all three cytokines (d) Th e frequency of single, double and triple 
cytokine positive CD8+ T cells. TIV and LAIV groups were combined at baseline, (N=42). **p<0.0001. 
A/Wisconsin/67/2005-H3N2 and B/Malaysia/2506/2004-Flu B; A/New Caledonia/20/1999-vH1N1, 
A/Solomon Islands/3/2006-sH1N1 and A/California/4/2009-pH1N1. * 
 
 




















Fig 3.6. Total cytokine+ CD4+ and CD8+ T cells were categorized into various phenotypic subsets based on 
the surface expression of CD45RA and CCR7. (a) Gates were set on total CD4+ and CD8+ T cells and then 
applied to cytokine+ cells. To determine the phenotype of cytokine producing cells, we included only those 
samples with > 30 cytokine+ events and cytokine+ frequencies >3x over background (b and c). Phenotypes 
of cytokine+ CD4+ (b) and CD8+ (c) T cells after ex vivo stimulation with various influenza viruses as 
indicated. TIV and LAIV groups were combined at baseline (N=42). 
 
3.4.5 Effect of seasonal vaccination on influenza-specific CD4 and CD8 T cell 
frequency 
We next examined, the effect of different seasonal vaccine delivery/formulation 
strategies on the magnitude and quality of CD4 and CD8 T cell responses. Fourteen 
days after intramuscular vaccination with TIV, we detected a significant increase in total 
cytokine producing CD4 T cells against influenza strains contained in the vaccine (Fig 
3.7a).  Interestingly, we also observed a significant increase in the frequency of 
influenza-specific CD4 T cells against antigenic variants not included in the vaccine 
including sH1N1 and importantly the pandemic 2009 H1N1 (pH1N1) virus, although the 
latter did not reach statistical significance (Fig 3.7a). By 28 days post vaccination, CD4 T 
cell frequencies against all strains, except sH1N1, had returned to levels similar to those 
prior to vaccination. The CD4 T cell response noted above was primarily directed against 
hemagglutinin (HA) as we observed a significant increase in CD4 T cells against HA 
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(derived from hemagglutinin of A/Wisconsin/67/2005 (H3N2)) but not against any of the 
internal proteins tested at day 14 post vaccination with TIV (Fig 3.7b). These data are 
consistent with the fact that the inactivated vaccine used in this study (Fluzone, Aventis 
Pasteur), is a split vaccine 
(www.fda.gov/downloads/BiologicsBloodVaccines/ApprovedProducts/UCM305089.pdf) 
predominantly composed of hemagglutinin (HA) with internal proteins present at much 
lower concentrations (234). In contrast to the CD4 T cell response to TIV, we did not 
observe any changes in virus or protein-specific CD8 T cells after vaccination (Fig 3.7c 
and d). 
We and others have previously reported weak antibody responses to LAIV in adult 
vaccine recipients (162,235).  It has therefore been suggested that T cell immunity may 
contribute to protection following LAIV (85). Indeed, we found that vaccination with LAIV 
induced a significant increase in total cytokine producing CD4 T cells against vH1N1 
(detected at 28 days post vaccination, p<0.05) and Flu B (detected at 14 and 28 days 
post vaccination, p<0.05) (Fig 3.7e). CD4 T cell frequencies against sH1N1 and pH1N1 
also showed a trend towards an increase at day 28 post-vaccination, although this did 
not reach statistical significance. When we examined the protein-specificity of the CD4 T 
cell response to LAIV, we did not observe any significant changes in CD4 T cell 
frequencies against any of the tested proteins (Fig 3.7f). In addition, we did not observe 
any changes in the frequency of total cytokine producing CD8 T cells against influenza 







Figure 3.7  Effect of seasonal vaccination on influenza-specific CD4 and CD8 T cell 
frequency 
TIV 
a                                                                               b. 
 




e.                                                                                    f. 
 
g.                                                                                    h.  
Fig 3.7. PBMCs were stimulated ex vivo with whole, β-propiolactone inactivated influenza viruses or peptide 
pools as indicated. The frequency of total cytokine positive (IFN-γ, TNF-α, IL-2 or any combination of the 
three cytokines) CD4 and CD8 T cells was enumerated at day 0 (baseline), day 14 and day 28 post-
vaccination with TIV (n=25) (a-d) and LAIV (n=17) (e-h). Individual values are represented as dots. *p<0.05, 




3.4.6 Effect of seasonal vaccination on influenza-specific T cell quality  
To determine if changes in the frequency of total cytokine producing cells was 
accompanied by changes in T cell quality, we next investigated the cytokine secretion 
profiles of CD4 and CD8 T cells at various time points after vaccination with TIV and 
LAIV. Interestingly, vaccination with TIV was associated with a reduction in the 
proportion of single cytokine producing cells in favor of double producers at day 14 and 
day 28 post vaccination (Fig 3.8). These changes were however not uniform and could 
only be detected against H3N2, Flu B (both present in seasonal TIV) and interestingly, 
against pH1N1 as well.   In contrast, no significant changes in cytokine secretion profiles 
were noted in CD8 T cells or in LAIV recipients (data not shown).  
 
Figure 3.8  Effect of TIV on T cell quality                                                                          
     















Fig 3.8. PBMCs form prior to vaccination (day 0) and 
day 14 and day 28 post vaccination with TIV were 
stimulated ex vivo with whole, β-propiolactone 
inactivated influenza viruses as indicated. The relative 
proportion of CD4 T cells making any one cytokine       , 
any two cytokines       or all three cytokines        was 
determined using multiparameter flow cytometry as 




Despite vaccination efforts, influenza remains a major cause of morbidity and 
mortality worldwide (2,236). The current vaccines show limited efficacy in vulnerable 
populations such as the elderly and in instances when there is poor antigenic match 
between vaccine and circulating strains (123). These limitations represent an important 
challenge for new vaccine efforts, particularly in light of the constant threat posed by 
pandemic strains which can be highly virulent and pathogenic (237,238).  
Current FDA guidelines for the assessment of immunological endpoints of vaccine 




Guidances/Vaccines/ucm074794.htm). Studies in animal models and more recently in 
humans, point to an increasingly important role for cellular immune responses in 
mediating cross-reactive or heterosubtypic immunity to influenza (78,81). In addition, 
induction of T helper cells following vaccination has been found to correlate with an 
increase in antibody titers in humans lending support to the notion that optimum antibody 
production requires concomitant T cell activation (68,79,239,240). Harnessing cellular 
immune responses to enhance antibody production as well as offer broad protection 
against a range of circulating and emergent pandemic strains would be of great benefit 
from a vaccination standpoint. Nevertheless, very little is known about influenza-specific 
T cell immunity or vaccination strategies that can induce such cellular responses, 
particularly in humans. Accordingly, in the present study we examined the cellular 
immune response to influenza. In addition, we used the commercially available seasonal 
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influenza vaccines as a tool to understand how different immunization routes and 
antigen formulations affect cell mediated immunity against influenza. 
Early studies examining the pathogenicity of the 2009 pandemic H1N1 virus (pH1N1) 
using animal models suggested increased virulence compared to seasonal influenza 
viruses (241-243). However, in humans, overall morbidity and mortality associated with 
pandemic H1N1 infections was low and comparable to seasonal influenza infections 
despite the poor cross-reactivity of antibodies to pH1N1 in most young adults (244-246). 
In our cohort, we were able to detect a high degree of cross-reactivity in influenza 
specific memory T cells compared to antibodies against drifted strains as well as pH1N1 
prior to vaccination. These observations are in line with previous studies that report a 
higher conservation of T cell epitopes compared to B cell epitopes between circulating 
seasonal H1N1 strains and pH1N1 (75). The presence of such broadly cross-reactive T 
cells may explain why most people did not become severely ill despite the low levels of 
pre-existing antibodies against pH1N1. This assertion is supported by previous studies 
demonstrating a key role for pre-existing T cells in mediating protection against severe 
disease in humans (78,81). Interestingly, Wrammert, et al. report the presence of rare 
populations of memory B cells that are broadly cross-reactive in nature, despite the 
absence of cross-reactive antibodies. They propose a model wherein expansion of these 
rare memory B cells following infection mediates protection from newly emerged 
influenza strains (87). The relative contribution of these different cell types to protective 
immunity is still not clear and warrants further investigation.  
More than a decade ago it was proposed that circulating memory T cells in humans 
could be divided into two distinct subsets on the basis of proliferative capacity and 
migration potential: central memory (TCM) cells that express CCR7 and CD62L (L-
selectin) and proliferate extensively and effector memory (TEM) cells that do not express 
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these markers and are less proliferative but capable of rapid effector function (233). 
While factors that favor the generation of one population over the other have not been 
fully identified, acute infections are thought to favor the generation of TCM whereas 
chronic infections as well as repeated antigenic stimulation are thought to progressively 
skew towards a TEM phenotype with a substantially reduced proliferative and IL-2 
producing capacity (247,248). Previous studies examining the phenotype of influenza-
specific T cells are divided: some have noted a preponderance of central memory T cells 
while others have reported primarily an effector memory phenotype (75,249). Our data 
suggest that these differences may in part be due to difference in the viral strains tested 
although the mechanisms that drive this differential response are still not clear. In 
general, we found that the majority of influenza-specific CD4 and CD8 T cells expressed 
a TEM phenotype (Fig 3.6b and c) and CD8 T cells in particular had a limited capacity to 
produce IL-2 (data not shown) consistent with the notion that repeated seasonal 
infections favors the generation of memory cells with an effector memory phenotype. 
Interestingly, as shown previously (250), we too found a sizeable proportion of cytokine+ 
T cells to have a naïve-like phenotype. It is tempting to speculate that these naïve-like 
memory cells may belong to a recently identified population of memory “stem cells” 
which have a high capacity for self-renewal and an ability to derive TCM, TEM and effector 
populations (251). An important unanswered question is the relative contribution of these 
memory subsets to protective immunity as well as the lineage relationship between 
them. On the one hand induction of TEM within non-lymphoid tissues may be desirable 
for vaccines against pathogens that replicate in peripheral tissues such as influenza 
(252-254). In support of this, a recent study showed that the presence of influenza-
specific memory CD8 T cells that expressed a TEM phenotype correlated with protection 
from severe disease (81). On the other hand, induction of self-renewing, proliferative TCM 
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or stem cell-like memory populations may confer long-term protection against infection 
(255-257). More studies are required to dissect the relative contribution of different 
memory CD4 and CD8 T cell subsets to protective immunity to influenza.  
The functionality of antigen-specific memory T cells has also recently emerged as an 
important predictor of protection (215). Reports from a number of different disease 
models in mice, non-human primates and humans suggest that memory CD4 and CD8 T 
cells that express multiple effector functions, such as concomitant production of IFN-γ, 
TNF-α and IL-2, constitute a higher quality response than their single-positive 
counterparts (59,189,249,258,259). Immunological mechanisms that drive the 
generation of specific functional profiles are poorly defined and represent a major hurdle 
in the rational design of new vaccines. One intriguing finding in this study was the 
reduced multifunctional potential of cross-reactive memory CD4 and CD8 T cells against 
pH1N1 compared to seasonal H1N1 viruses. While our data clearly demonstrated that 
memory CD4 and CD8 T cells established by seasonal infections and/or vaccinations 
recognize conserved epitopes in novel influenza viruses, some studies suggest that as 
many as half the conserved epitopes have at least one amino acid substitution thereby 
affecting the avidity of binding (260,261).  Recent work in mouse models suggest a 
correlation between T cell functionality and avidity such that quality of the CD8 T cell 
response is enhanced in highly avid CD8 T cells (262). The reduced polyfunctionality of 
cross-reactive CD4 and CD8 T cells noted in this study may therefore reflect reduced 
functional avidity and warrants further investigation. 
Another striking finding in this study was that while TIV and LAIV significantly 
enhanced the overall magnitude of the influenza-specific CD4 T cell response, only TIV 
induced a modest, yet significant, expansion of double cytokine producing cells. These 
data lend support to the idea that different vaccine types can differentially influence on 
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the multifunctional potential of the ensuing memory response (215). This finding is in 
keeping with studies in animal models that similarly noted a significant increase in 
double cytokine producing cells after subunit vaccination but not after administration of a 
live vaccine (230).  
Several independent lines of evidence indicate that the successful vaccination 
strategies against pathogens such as malaria, tuberculosis, HIV and influenza will likely 
require the induction of robust cellular immune responses (206,263). This study as well 
as other demonstrate that in humans, pathogen-specific T cell responses are functionally 
and phenotypically heterogeneous and that simultaneous evaluation of T cell phenotype 
and function can provide a more sensitive and specific surrogate than T cell frequency 
alone. Flow cytometry is arguably the most advanced technology currently available for 
the immunophenotyping of T cells (264). However, multiparameter flow cytometry poses 
several technical and analytical problems including variability in reagents, sample 
handling and instrument settings. The use of pre-configured lyophilized reagents 
“lyoplates” has previously been shown to reduce variability in a multi-site study 
(224,225). In this study we extended this assay to include whole viral stimulations in 
addition to previously tested peptide pool-based approaches. Peptide based approaches 
alone are limited by the number of epitopes that can be examined and the use of 
overlapping peptides that cover the entire genome of the virus is expensive and may be 
impractical in larger trials. Stimulation with whole virus preparations on the other hand 
can enhance the sensitivity of detection of virus specific T cells against previously 
defined and undefined epitopes in a cost effective manner. In this study, we were able to 
detect robust T cell responses to whole inactivated viruses as well as peptide pools. 
Interestingly, despite using inactivated influenza viruses for stimulation of T cells, we 
were able to detect robust CD8 T cell responses suggesting effective cross-presentation 
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of exogenous antigens as reported elsewhere (265).  Data analysis represents another 
major bottleneck and source of variability in multiparameter flow cytometry assays (266). 
Advances in automated gating strategies (267) as well as the development of newer 
software that allow for high-dimensional data analysis (268) represent crucial next steps 
in the standardization of flow cytometry assays and increasing their ease of use.  
One of the goals of this study was to compare the impact of two different vaccination 
platforms on the development of antigen-specific T cell responses. Due to practical 
considerations, this study only examined peripheral T cells responses and not those in in 
local tissue, namely the lung. This sampling bias is particularly relevant when 
considering the immune response to a mucosally delivered vaccine such as LAIV. 
Indeed, several studies have noted the presence of a stable population of influenza-
specific tissue resident memory T cells (TRM) in the lungs of mice and humans that are 
distinct from circulating memory T cell subsets described earlier (269,270). It has been 
suggested that these highly localized memory T cells may act as a first line of defense 
against influenza (271) and may be more greatly impacted by mucosal vaccines such as 
LAIV than the peripheral responses measured in this study. Therefore caution must be 
used in interpreting our finding of stronger CD4 T cell responses following vaccination 
with TIV compared to LAIV.  Future studies in which TRM populations are examined 
through direct bronchial sampling may provide more insight into the immunological 
underpinning of LAIV. 
To our knowledge, this study represents the most comprehensive examination of 
influenza-specific T cell immunity in humans. We have made several key observations 
regarding the heterogeneity of influenza-specific T cells as well as demonstrated a 
differential impact of the two seasonal vaccines on the magnitude and quality of this 
response. Future studies are required to determine if the vaccine induced improvement 
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in T cell quality or cross-reactivity observed in this study will serve to limit disease 










We examined the impact of IL-10 deficiency on disease outcome following lethal 
infection with influenza.  We found that IL-10 deficient mice had significantly higher 
survival rate compared to WT mice suggesting a pathogenic role for IL-10.  The higher 
survival in Il10-/- correlated with improved lung function and significantly reduced 
pulmonary injury. Surprisingly, despite increased expression of several proinflammatory 
cytokines including TNF-α, IL-6 and IFN-γ, Il10-/- mice did not have lower pulmonary viral 
load. However, correlating with improved survival, lungs of Il10-/- mice had significantly 
higher levels of IL-22 and IL-22 expressing CD4 T cells. IL-22 is a cytokine that has 
previously been shown to be important in mediating recovery from influenza infection. 
Interestingly, protection in Il10-/- was found to be independent of IL-22 as Il10-/-Il22-/- mice 
had survival rates similar to that of Il10-/- mice. Finally, we show that impact of IL-10 on 













Seasonal influenza infections cause substantial morbidity and mortality resulting in 
an estimated 250,000-500,000 deaths worldwide every year. Young children and adults 
over the age of 65 as well as those with chronic medical conditions greatly increases the 
risk of developing severe complications with seasonal influenza (272,273). Despite 
having a lower risk of complications, around 6000 to 7000 young, healthy individuals 
between 18-64 years of age succumb to seasonal infections every year in the United 
States. During influenza pandemics, this number is typically much higher. During the 
1918 pandemic, for instance, it was estimated that individuals between the ages of 20-
40 accounted for approximately half of the total influenza deaths (274). Similarly, in 
2009, young adults were at highest risk for influenza-related morbidity and mortality 
(275). 
Pneumonia and the acute respiratory distress syndrome (ARDS) account for majority 
of the influenza-related complications during severe seasonal and pandemic infections 
and is most commonly categorized as primary viral pneumonia or a secondary bacterial 
pneumonia (276). Primary viral pneumonia occurs when the viral infection extends 
distally to the lung resulting in severe acute alveolar injury (also called diffuse alveolar 
damage) characterized by the formation of hyaline membranes lining the alveoli, 
necrosis of alveolar epithelium, flooding of alveolar lumen by edema fluid and substantial 
intra-alveolar hemorrhage in addition to necrotizing bronchitis and bronchiolitis 
(113,276). This pulmonary injury is accompanied by an elevated macrophages and 
lymphocytes in pulmonary infiltrates as well as a significant increase in pro-inflammatory 
cytokines and chemokines in serum (99,277-280). Findings in mice and non-human 
primate models of infection closely mirror that of humans (281). The significant increases 
in cytokine and chemokines and the corresponding immune dysregulation, otherwise 
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called the “cytokine storm”, is thought to, in part, underlie the observed pathology during 
primary viral pneumonia. Indeed, pharmacological interventions which blunt overall 
levels of pulmonary inflammation can significantly enhance survival in animal models, 
lending further support to this hypothesis (282). Similarly, reducing inflammatory cell 
recruitment, particularly innate immune cells, into pulmonary tissue has also been shown 
to markedly improve survival in mice (96).  
IL-10 is a potent anti-inflammatory cytokine with a key role in limiting inflammatory 
and autoimmune pathologies (283). The importance of IL-10 in controlling inflammation 
is evident in numerous models including Toxoplasma, Listeria, Plasmodium, 
experimental autoimmune encephalomyelitis (EAE) and models of asthma, where Il10-/- 
mice develop severe pathological lesions due to excess inflammation (284-289). The 
substantial immunopathology observed in Il10-/- suggest that the absence of IL-10 
cannot be compensated by other regulatory mechanisms and that it plays a non-
redundant and crucial role in controlling inflammation in vivo. Somewhat paradoxically, 
IL-10 has also been associated with detrimental disease outcomes due to its ability to 
suppress the development of an effective immune response. For instance, during 
infection with Leishmania, elevated IL-10 has been linked with increased parasite burden 
in animal models and humans (290-292). Similarly, IL-10 has also been shown to 
negatively affect clearance of M. tuberculosis and lymphocytic choriomeningitis virus 
(LCMV) in animal models (293,294) 
Interestingly, while IL-10 production has been described following influenza infection 
in mice and humans, its role in influenza pathogenesis is not clear (295-298). In humans, 
high IL-10 levels are associated with negative outcomes in hospitalized individuals 
suggesting that IL-10 expression during influenza infection may be detrimental to the 
host (107-109). However, studies in animal models have yielded conflicting results with 
82 
 
one study suggesting that IL-10 expression is critical in controlling pulmonary 
inflammation and injury (110) while other studies suggest that IL-10 is pathogenic during 
influenza infections (112,299).  
In this study, we utilized Il10-/- mice to characterize the role of IL-10 in inflammatory 
cell recruitment, development of pulmonary pathology and ultimately respiratory 
dysfunction during lethal influenza infections in vivo. The data presented in this chapter 
suggest that IL-10 contributes to influenza induced pulmonary pathology and vascular 
dysfunction without significantly affecting viral clearance.  Future studies aimed at 
elucidating the effect of IL-10 on vascular permeability may provide more insight into 





4.3 Materials and Methods 
Mice 
Female WT, Il10-/-, Il22-/- or Il10-/-xIl22-/- were between 9-12 weeks old at the time of 
virus infection. All lines were on the C57Bl/6 background. WT mice were obtained from 
Jackson Laboratory whereas, Il10-/- were bred in the animal breeding facility at Johns 
Hopkins. WT and Il10-/- mice were negative for helicobacter. Il22-/- mice were kindly 
provided by Dr. Ouyang from Genentech and were backcrossed to Il10-/- to generate 
Il10-/-xIl22-/- mice. Experimental animal procedures were conducted in accordance with 
the Johns Hopkins Animal Care and Use Committee guidelines. 
 
Virus stocks, titers and infections 
Egg-grown, mouse-adapted influenza A virus, A/Puerto Rico/8/34 (A/PR8) was 
generously provided by Dr. Maryna Eichelberger at the U.S. Food and Drug 
Administration. A/WSN/33 was a kind gift from Dr. Andrew Pekosz at the Johns Hopkins 
School of Public Health. Virus stock titers or lung viral loads were determined by 
endpoint dilution assay and expressed as tissue culture infectious dose 50 (TCID50) as 
described elsewhere (110). Briefly, Madin-Darby canine kidney (MDCK) cells were 
incubated with 10-fold serial dilutions of viral stocks or whole lung homogenates from 
influenza infected mice for 3 days at 37ºC in a humidified atmosphere of 5% CO2. After 3 
days, supernatants were collected and mixed with half volume 0.5% chicken red blood 
cells (CBT farms, Federalsburg, MD), the agglutination pattern read and TCID50 values 
calculated using the method of Reed and Muench. 
For in vivo infections, mice were anesthetized with intramuscular injection of 
Ketamine/Xylazine (80 mg/Kg and 6 mg/Kg, respectively) and infected intranasally with 
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30 µl of Phosphate Buffered Saline (PBS) containing A/PR/8 or A/WSN/33 at doses 
indicated in the results. 
 
Real-time PCR for viral load and cytokine gene expression 
At different time points after intranasal infection, mice were euthanized and lungs 
were perfused by injecting 20 ml of PBS into the left ventricle of the heart. For cytokine 
gene expression studies and viral load determination, the left lung was placed in TRIzol 
(Cat. No: 15596-018, Life Technologies). RNA was isolated from whole lung 
homogenates using TRIzol and reverse transcribed using first-strand cDNA synthesis kit 
(Cat No. 18080-051, Invitrogen), according to manufacturer’s protocol. Quantitative PCR 
was performed using SYBR Green primers for cytokine genes (Appendix: Table 1). For 
viral load quantification, the polymerase (PA) gene of A/PR8 was amplified using 
Taqman primers and probes as described elsewhere (299). The fold increases in relative 
signal to that of uninfected samples was determined by the ΔΔCT calculation as 
recommended by Applied Biosystems. All analyses were performed on an ABI 7300 
Real-Time PCR System. 
 
Cytokine analyses in bronchoalveolar lavage fluid (BALF) 
Mice were killed at the indicated time points by an overdose of ketamine and 
xylazine and were subjected to bronchoalveolar lavage (BAL) 3 times with a total of 1 ml 
of phosphate buffered saline (PBS) instilled via the trachea. BAL fluid (BALF) was 
centrifuged at 2000 rpm for 5 minutes at 4ºC and the supernatant was used for 
subsequent measurement of cytokines. Levels of IL-6, TNF-, CCL2, IFN-, IL-12p70 
and IL-10 in BALF was determined using mouse proinflammatory BD CBA kit (Cat No. 
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552364, BD Biosciences). Levels of IL-22 was determined using FlowCytomix (Cat No. 
BMS86022FF, eBiosciences). Levels of IL-17 were determined using FlowCytomix (Cat 
No.BMS86001FF, eBiosciences) and BD Flex Set (Cat No.560283, BD Biosciences). 
 
Pulmonary function analysis 
Animals were anesthetized with Ketamine and Xylazine as described above and 
cannulated with an 18-guage stub needle cannula via the trachea. Measurement of DFCO 
was performed as mentioned elsewhere (300). Briefly, 0.8 ml of a gas mixture of 
approximately 0.5% neon, 0.5% CO and balance air was used to inflate the lung via the 
cannula. After waiting 9 seconds, 0.8 ml was withdrawn from the lung and injected into a 
desktop Gas Chromatograph (Inficon Micro GC model 3000A). The DFCO is defined as 1- 
(CO9/COc)/ (Ne9/Nec) where the subscripts c and 9 stand for the calibration gas injected 
and gas withdrawn after 9 seconds. Following DFCO measurement, animals were 
artificially ventilated at a rate of 120 breaths/minute and a tidal volume of 0.2 ml. One 
minute after a 5 second deep inspiration, dynamic elastance was measured as 
described elsewhere (301).  
 
Histopathological examination and TUNEL staining 
For histopathological examination, lungs were inflated at a constant pressure of 30 
cm H2O for 5 minutes with 10% neutral buffered formalin (NBF). Trachea were tied off 
and intact lungs were excised from the chest cavity and submerged in 10% NBF for at 
least 48 hours prior to paraffin embedding. Lungs were stained with hematoxylin and 
eosin (H&E) and blindly evaluated for pathological changes. For postmortem studies, 
lungs were collected within 5 hours of death.  For day 8 post-infection, mouse lungs 
were collected after pulmonary function analysis.  
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For the detection of apoptotic cells, Tdt-mediated dUT-biotin nick-end labeling 
(TUNEL) staining was performed using the in situ cell death detection kit (Cat No.11 684 
795 910, Roche) as per manufacturer’s instructions. Slides were counter stained with 
DAPI to define nuclei. Rate of apoptosis was calculated by dividing the number of 
TUNEL positive cells by the total number of nuclei (DAPI+) in any given field of view. 
The prevalence of apoptosis for a given lung section was averaged over 5 randomly 
selected fields of view at 40x magnification.  A total of 9 slides per group were analyzed 
over two independent experiments.  
 
Flow cytometry and intracellular cytokine staining  
For flow cytometric evaluation of pulmonary leukocyte populations, single cell 
suspensions were made from whole lungs by mechanical disruption using the Miltenyi 
gentleMACS cell dissociator (Cat No. 130-093-235) according to manufacturer’s 
protocol. Single cell suspensions were stained with LIVE/DEAD Fixable Dead Cell Stain 
Kits (Cat No: L34959, Invitrogen) according the manufacturer’s instructions followed by 
incubation with anti-CD16 Fc Block  (Cat No:553142, BD Biosciences) for 20 minutes on 
ice to block FcRs. Cells were then stained with the following antibodies CD11b-PerCP-
Cy5.5 (550993, BD Biosciences), CD11c-APC (550261, BD Biosciences), MHC II(I-A/I-
E)-FITC (11-5321, eBiosciences), Ly6G-PE (551460, BD Biosciences), Ly6C-APC (17-
5932-80, eBiosciences), CD4-APC-H7 (560181, BD Biosciences), CD8-Pacific Blue 
(558106, BD Biosciences), CD3-PE-Cy5 (15-0031-81, eBiosciences) and NK1.1-PE 
(553165, BD Biosciences) in wash buffer (1x PBS with 0.5% BSA) for 30 minutes on ice. 
Following surface stain, cells were washed twice in wash buffer.  
For intracellular detection, single-cell suspensions of lungs were prepared as 
described above and restimulated for 5 hours with 40 ng/ml Phorbol-12-myristate-13-
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acetate (PMA; Cat No:524400, Calbiochem) plus 2 ug/ml Ionomycin (Cat No: 407952, 
Calbiochem) at 37°C with brefeldin A (Cat No:51-2301KZ, BD Biosciences) added 
during the last 3 hours. Cells were washed, surface-stained as described above and 
then fixed and permeabilized by incubating in Cytofix/Cytoperm (BD Biosciences) for 20 
minutes on ice. Cells were washed in Perm/Wash buffer (BD Biosciences) and 
immunostained with anti-IFN-γ-PE-Cy7 (557649, BD Biosciences), anti-IL-17-Alexa 
Fluor 488 (560220, BD Biosciences) and anti-IL-22-PE (12-7221-82, eBiosciences) in 
Perm/Wash buffer for 30 minutes on ice.  FACS analysis was performed on a BD 
Bioscience LSR II and FlowJo (Tree Star) analysis software. 
 
Statistical analysis 
The log rank test was used to test for significant differences in Kaplan-Meier survival 
curves. Unpaired, two-tailed Student’s t tests, α=0.05, were used to determine if there 




4.4.1 IL-10 contributes to increased morbidity and mortality 
To examine of the role of IL-10 in influenza pathogenesis, Il10-/- and WT mice were 
infected with different doses of influenza A/PR/8 and monitored daily for weight loss, as 
a measure of morbidity, and survival. As shown in Fig 4.1a, Il10-/- mice had significantly 
less weight loss than WT mice throughout the course of acute infection. This correlated 
well with higher survival rates, suggesting that IL-10 expression contributes to influenza 
disease severity. It should be noted that the weight loss was significantly higher for WT 
mice starting at day 5 post-infection until day 9 beyond which the data are subject to 
survival bias. To determine if this effect was dependent on the infectious dose, Il10-/- and 
WT mice were challenged with a higher dose (50 TCID50/mouse) and a similar reduction 
in weight loss and mortality was observed in Il10-/- compared to WT mice (Fig 4.1b). 
Mice were infected with a dose of 25 TCID50/mouse for the rest of the study. 
 
Figure 4.1  Mortality and weght loss following infection with influenza A/PR/8 





Fig 4.1. Il10-/- and WT were infected intranasally with (a) 25 TCID50 or (b) 50 TCID50A/PR/8. Weight loss and 
survival were assessed daily for a period of 21 days. (n=38-40 mice/group).  Data were combined from 4 
independent experiments, **p<0.01, log rank test, *p<0.01, student ttest)   
 
4.4.2 Il10-/- mice have decreased pulmonary pathology compared to WT 
Next, to determine if IL-10 influenced pulmonary pathology, histological examination 
of lungs was performed postmortem in animals that had succumbed during the course of 
infection as well as at day 8 post-infection. Similar to findings in humans, postmortem 
examination of Il10-/- and WT lungs revealed pathological changes consistent with 
diffuse alveolar damage (DAD) characterized by the presence of hyaline membranes, 
infiltration of inflammatory cells and significant edema and hemorrhage (Fig 4.2a).  
Interestingly, while these pathological changes could be observed as early as day 9 
post-infection in WT mice, similar changes became prominent only around day 14 in Il10-
/- (data not shown).  In mice that were euthanized at day 8 post-infection, histopathology 
confirmed patchy involvement of lungs and generally less airway involvement in Il10-/- 
compared to WT (Fig 4.2b and c). In addition, TUNEL staining at day 8 post-infection 
demonstrated a significantly lower number of apoptotic cells in the lungs of Il10-/- 
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compared to WT mice (Fig 4.2d and e). Taken together, these data suggest that IL-10 
deficiency results in a reduction and/or delay in pulmonary injury during acute infection 
leading to enhanced survival. 
 









































Figure 4.2. WT and Il10-/- mice were infected with A/PR/8 at a dose of 25 TCID50. (a) Lungs were removed 
immediately post-mortem and fixed in 10% neutral buffered. H&E stained sections were examined blindly for 
pathology. Hyaline membrane (single arrow) and hemorrhage (double arrow) noted in Il10-/- and WT lungs (b 
and c) Il10-/- and WT mice were euthanized at day 8 post-infection and H&E stained lung sections were 
examined. (b) Presence of inflammatory exudate noted in Il10-/- and WT lungs (green circle). Perivascular 
hemorrhage (arrow) noted in WT lungs. (c) Alveolar inflammation and intraalveolar hemorrhage (arrow) 
more prominent in WT compared to Il10-/-. (d) Induction of apoptosis was identified by in situ TUNEL staining 
of formalin fixed lung sections at day 8 post-infection. Slides were counter stained with DAPI (blue). 
Apoptotic cells are in stained in green (arrows) and nuclei are stained blue (e) The percentage of apoptotic 
cells per field of view was quantified as described in the methods (n=9 mice/ group from 2 independent 




4.4.3 IL-10 does not affect viral replication 
To determine if reduction in lung pathology was due to reduced viral replication in the 
lung, viral loads were determined at various time points after infection in whole lung 
homogenates by RT-PCR (Fig 4.3). Infectious viral load in whole lung homogenates 
were measured by end point dilution assay and were similar to RT-PCR results (data not 
shown). As shown in Fig 4.3, viral loads were similar in Il10-/- and WT mice throughout 
the course of infection suggesting that IL-10 does not play a role in controlling viral 
replication and that viral load does not account for histopathological difference in 
pulmonary injury between Il10-/- and WT mice. 
 







Fig 4.3. WT and Il10-/- were infected with 25TCID50/mouse of A/PR/8. Lungs were isolated at the indicated 
time points and viral load was quantified by semi-quantitative real-time PCR in whole lung homogenates at 
the indicated time points (n=8-10 mice/group/time point from 2 independent experiments) 
 
4.4.4 Improved pulmonary mechanics in Il10-/- mice compared to WT 
To determine if pathologic effects associated with influenza infection resulted in 
altered lung function, we assessed the diffusion factor for carbon monoxide-DFCO (a 
metric that reflects the gas-exchanging ability of the mouse lung) and pulmonary 
93 
 
elastance during the course of infection (Fig 4.4). Consistent with histological findings in 
the lung during infection, changes in pulmonary mechanics were noted in both groups 
throughout the course of infection. Compared to WT mice, however, Il10-/- had 
significantly higher DFCO values at day 6 and day 8 post-infection suggesting an 
enhanced capacity for gas exchange (Fig 4.4a). In addition, lungs from Il10-/- mice had 
significantly reduced lung elastance compared to WT mice at day 8 post-infection (Fig 
4.4b). Taken together, these data suggest that in addition to reduced pulmonary 
pathology, Il10-/- mice also displayed significantly enhanced pulmonary function 
compared to WT mice. 
 
Figure 4.4  Il10-/- have improved pulmonary function compared to WT 
a.                                                                    b.                                                                                
                                         
Fig 4.4.  WT and Il10-/- mice were infected with A/PR/8 at a dose of 25 TCID50. On the stated days (a) 
Diffusion factor of carbon monoxide (DFCO) and (b) pulmonary elastance were measured (n=6-12 mice/ 





4.4.5 IL-10 deficiency does not substantially affect the recruitment of leukocyte 
populations, but results in an increase in proinflammatory cytokines 
Because excessive inflammation is associated with severe influenza infections (95), 
we next examined the recruitment of inflammatory cell into the lungs of WT and Il10-/- 
mice (Fig 4.5). Interestingly, we detected no significant differences in any major 
infiltrating leukocyte populations including NK cells (CD3-Nk1.1+), neutrophils 
(CD11b+Ly6g+Ly6c-SSChi) and dendritic cells (CD11b+CD11chiMHCIIhi and CD11b-
CD11chiMHCIIhi), at any time point post-infection. There was a significant increase in 
CD4+CD44+ T cells at day 3 and day 5 post-infection in WT mice compared to Il10-/- , 
however, the numbers were similar by day 7 post-infection. No differences were 
observed in the recruitment of CD8 T cells between Il10-/- and WT mice.  
The primary function of IL-10 is to negatively regulate the secretion of pro-
inflammatory cytokines from leukocytes (283). Therefore, somewhat expectedly, the 
levels of numerous cytokines, including IFN-, TNF-, IL-6 and IL-22 were elevated in 
the BALF of Il10-/- compared to WT (Fig 4.6a). Interestingly, no IL-17 could be detected 
at any time post infection in Il10-/- or WT BALF (data not shown). To rule out the 
possibility that the increased levels of cytokines in the BALF was due to increases in 
total protein leakage into the airways, total protein was also measured in BALF of Il10-/- 
and WT mice. However, no differences were observed in the levels of total protein 
between ll10-/- and WT (Fig 4.6b). In addition, consistent with elevated IL-22 and IFN-γ 
levels in the BALF, we also observed a significantly higher number of IL-22 and IFN-γ 
producing CD4 T cells in the lungs of Il10-/- compared to WT mice (Fig 4.6c). No 
difference could be detected in the recruitment of IFN- γ producing CD8 T cells (data not 
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shown). No IL-22 producing CD8 T cells could be detected in Il10-/- or WT lungs (data not 
shown).  
 
Figure 4.5  Recruitment of leukocytes following infection with influenza 
 
Fig 4.5. WT and Il10-/- mice were infected with 25 TCID50 of A/PR/8. Changes in the numbers of immune 
cells measured from whole lung by flow cytometry at days 0, 3, 5 and 7 post-infection. n=5-6 mice/ 





















Fig 4.6 WT and Il10-/- mice were infected with 25 TCID50 of A/PR/8. (a and b) At the indicated days post-
infection, bronchoalveolar lavage fluid (BALF) was isolated and analyzed for protein levels of the stated 
cytokines (a) or total protein (b) (n=7-10 mice/ group/time point combined from 2 independent experiments. 
*p<0.05, **p<0.001). (c) Single cell suspensions of whole lungs were stimulated with PMA and Ionomycin in 
the presence of Brefeldin A and intracellular staining was performed for IL-22 and IFN-γ (n=3 





4.4.6 IL-22 does not mediate enhanced survival to influenza challenge in Il10-/- mice 
Previously published studies have identified an important role for IL-22 in mediating 
pulmonary repair following infection with influenza (302,303). Therefore, we explored the 
possibility that attenuated disease severity observed in Il10-/- mice was due to an up-
regulation of IL-22 expression.  To determine if there was a causal link between IL-22 
and less disease in Il10-/-, we generated Il10-/-Il22-/- mice and then challenged them with 
a lethal dose of influenza A/PR/8 (25 TCID50/mouse). Interestingly, despite numerous 
studies linking IL-22 expression with improved morbidity in WT mice, as shown in Fig 
4.7, survival and weight loss in Il10-/-Il22-/- mice was similar to that seen in Il10-/-. These 
data suggest that increased production of IL-22 in Il10-/- mice does not affect disease 
outcomes. 
 







Fig 4.7. Il10-/-Il22-/- , Il10-/- and WT mice were infected with 25 TCID50 of influenza A/PR/8 and monitored 
daily for survival and weight loss (n=20 mice/group from 2 independent experiments 
 
                                                                                                         -WT    
                                                                                                          -Il10-/-   
                                                                                                         -Il10-/-Il22-/-          
98 
 
4.4.7 The absence of IL-10 in A/WSN/33 infected mice does not affect disease 
outcome 
Influenza viruses display a remarkable heterogeneity in terms of their ability to cause 
disease in humans. For instance, the highly pathogenic avian influenza strain, H5N1, is 
estimated to have a case fatality rate of approximately 60% compared to less than 0.1% 
with seasonal influenza viruses 
(www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/in
dex.html.).  Similarly commonly used mouse-adapted influenza viruses can also differ in 
their virulence with A/PR/8 representing a highly virulent strain and A/WSN/33 a less 
virulent one (304). Therefore, we next questioned whether IL-10 deficiency would also 
be beneficial during a less severe viral lung infection. To this end, we infected Il10-/- and 
WT mice with different doses of the less virulent A/WSN/33 strain and followed weight 
loss and survival. Surprisingly, we found that in contrast to the negative impact IL-10 had 
on disease outcome in A/PR/8 infected mice (Fig 4.1), it had no effect on disease 
progression in A/WSN/33 infected mice in terms of survival or weight loss (Fig 4.8a and 
b). To rule out the possibility that IL-10 may not be expressed during A/WSN/33 
infection, IL-10 gene expression was measured by RT-PCR in whole lung homogenates. 
As shown in Fig 4.8c, IL-10 expression profiles in A/PR/8 and A/WSN/33 infected lungs 
were identical and peaked at day 7 post-infection suggesting that both highly virulent 








Figure 4.8  Mortality and weight loss following infection with influenza A/WSN/33 
a.   
 





Fig 4.7. Il10-/- and WT mice were infected with (a) 103 TICD50/mouse and (b) 104 TICD50/mouse of 
A/WSN/33 and monitored over a period of 21 days for survival and weight loss (n=30 mice/group) (c) WT 
mice infected with A/PR/8 or A/WSN/33 and on the stated days lungs were analyzed for IL-10 gene 





Influenza virus pneumonia is characterized by the rapid development of pulmonary 
injury and is typically associated with poor disease outcomes (34,35). Both viral 
pathogenicity factors and a dysregulated immune response have been implicated in the 
induction of pulmonary failure (53,305,306). However, the immunological mechanisms 
that govern the development of pulmonary injury are poorly understood. Therefore in this 
study, we examined the role of the anti-inflammatory cytokine IL-10 in regulating 
immunopathology during influenza infections. 
The primary function of IL-10 is in modulating the expression of cytokines and 
chemokine such as TNF-α, IL-6, IL-1β, CCL-2 and IL-8 as well as down regulating the 
expression of co-stimulatory molecules on APC’s, thereby affecting their ability to initiate 
and sustain an inflammatory response (reviewed in (283)). By doing so, IL-10 has also 
been shown to have a profound impact on the development of Teffector subsets including 
Th1, Th2 and Th17 cells (307,308). In keeping with its canonical functions, we too found 
that expression of IL-10 during influenza infections served to regulate the expression of 
several key proinflammatory cytokines and recruitment of Teffector populations into 
pulmonary tissue. Interestingly, while we and others (112) did not detect any IL-17 
protein in the BALF of WT or Il10-/- mice (data not shown) nor any increase in IL-17 
producing CD4+ or CD8+ T cells (data no shown), McKinstry, et al., noted significant 
increases in IL-17 producing CD4 T cells in the lungs of Il10-/- compared to WT. One 
potential explanation for these conflicting results is that different strains of mice were 
used, ie. we used C57Bl/6 mice, whereas McKinstry, et al. utilized BALB/c mice.  Indeed 
other studies have similarly noted mouse strain-specific expression patterns of IL-17 
(309). Nevertheless IL-17 production in lung tissue or the recruitment of other cell types 
capable of making IL-17 cannot be ruled out.   
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During chronic infections, the potent anti-inflammatory activity of IL-10 has been 
shown to interfere with effective clearance of pathogens such as Leishmania (292), 
lymphocytic choriomeningitis virus (LCMV)(293) and M. tuberculosis (310). However, 
during acute influenza infection, we observed no negative effect of IL-10 on viral 
replication. Similarly IL-10 had no effect on viral replication in a mouse model of 
respiratory syncytial virus (RSV) (311).  Taken together these data suggest that, at least 
in the context of acute respiratory viral infection, the regulatory effects of IL-10 may not 
significantly impact the development of anti-viral effectors.  
The role of IL-10 in influenza has been somewhat controversial: While Sun J, et al.,  
noted significantly lower survival rates in mice treated with IL-10R blocking antibodies 3 
days post-infection, McKinstry KK., et al. observed significantly higher survival rates 
when antibody administration was started prior to infection or when IL-10 was genetically 
ablated (ie. Il10-/-), similar to findings in this study (110,111). These conflicting data 
suggest that perhaps the temporal expression and therefore the cellular source of IL-10 
may be key in dictating disease susceptibility. IL-10 is a pleiotropic cytokine that is 
secreted by many different cell types including macrophages, CD4 and CD8 T cells, B 
cells and epithelial cells (283). In the context of influenza, while some studies have 
demonstrated that pulmonary CD4 and CD8 T cells are an important source of IL-10 
(110,111), others report significant IL-10 expression even after T cell depletion indicating 
the presence of other sources of IL-10 (112).  It will be interesting in future studies to 
more rigorously determine the requirement for specific cellular sources of IL-10 in 
influencing disease susceptibility to influenza infections using cell type-specific knock out 
strategies such as the Cre/loxP system. 
During influenza infections, virus replication and the presence of inflammatory 
mediators has been shown to result in the apoptosis of pulmonary epithelial cells thereby 
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leading to substantial tissue damage and decreased pulmonary function (304).  At day 8 
post-infection, while there were signs of active apoptosis in WT lungs, Il10-/- lungs 
appeared to have cleared most apoptotic cells, suggesting a possible acceleration of 
tissue repair/reduction of pulmonary injury in IL-10 deficient lungs. In agreement with 
this, another study found that IL-10 inhibited wound closure and healing in cutaneous 
model of injury by inhibiting the activation of (312).  
Repair and remodeling of pulmonary tissue after damage is a complex process that 
involves the coordinated action of cytokines, chemokines, growth factors and 
extracellular matrix proteins (reviewed in (313)). During the repair process, local and 
newly recruited progenitor cells undergo proliferation, differentiation and migration to re-
establish the denuded epithelial layer. Members of the epidermal growth factor (EGF) 
(314) (315) and fibroblast growth factor (FGF) families (reviewed in (316)) have long 
been known to be involved in this process. However, a role for inflammatory mediators in 
tissue repair and homeostasis has also been proposed.  IL-22, a member of the IL-10 
family, has recently emerged as an important player in the maintenance of tissue 
homeostasis. IL-22 can act directly on epithelial cells and induce the expression of gene 
involved in wound healing via STAT3 signaling (317). Consequently, IL-22 has been 
shown to promote mucosal tissue repair during influenza infections (115,303). Despite a 
significant up regulation of IL-22 in Il10-/-, as previously reported (111), our data indicate 
the protection in Il10-/- does not depend on IL-22.  Further studies will thus be required to 
determine the specific mechanisms responsible for decreased/delayed pulmonary injury 
noted in Il10-/- mice but it is tempting to speculate that regulation of immune or non-
immune mechanisms of tissue repair are involved. For instance, IL-1β has been shown 
to augment alveolar epithelial migration and cell spreading by inducing the expression of 
EGF or TGF-α in an in vitro model (318,319). Similarly innate lymphoid cell recruitment 
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into influenza-infected lungs has been shown to be critical in promoting airway epithelial 
cell integrity and lung function via the secretion of amphiregulin (116) (a member of the 
EGF family (320)). The regulation of these effectors by IL-10 is not well characterized 
and warrants further study. 
One intriguing finding in this study was the previously unreported virus-specific effect 
of IL-10 on disease outcome.  Influenza viruses can differ remarkably in their ability 
cause cell death and pulmonary tissue destruction, with highly virulent strains generally 
resulting in significantly greater pathology. This difference in pulmonary damage can be 
driven by differential ability of influenza viruses to directly cause apoptosis in infected 
cells (321). Indeed, inserting the NA and PA gene segments from A/PR/8 into less 
virulent strains was found to dramatically increase the levels of apoptosis in cultured 
MDCK cells in vitro (322). Alternatively, influenza viruses can differ in their ability to 
recruit and/or activate inflammatory cells, thereby indirectly causing increased 
pulmonary damage (89,237,304). In light of our data showing continued presence of 
apoptotic cells in WT compared to Il10-/- mice, one could speculate that the suppression 
of tissue repair/enhancement of tissue injury by IL-10 dependent mechanisms may more 
directly impact disease outcomes with highly virulent strains such as PR/8 compared to 
less virulent infections. Further studies are required to elucidate the mechanism behind 









CHAPTER 5: General discussion 
Despite vaccination efforts, influenza remains one of the leading causes of death in 
the United States (http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf). A major 
hurdle in the development of new therapeutic approaches and vaccines is our limited 
understanding of host factors that contribute to protective and pathogenic responses to 
infection. While the majority of past work has focused on neutralizing antibodies as the 
sole correlate of protection against infection, emerging data suggest that other 
components of the immune system may not only play an important role in protective 
immunity but, in fact, could also cause substantial tissue damage. The work presented in 
this dissertation contributes significantly to the better understanding of immune 
mechanisms that contribute to protective immunity during vaccination and pathologic 
host responses during lethal influenza infections in vivo. 
Vaccines are widely regarded as one of the most successful public health 
interventions to date, with a 95-99% reduction in the incidence of vaccine preventable 
diseases in the United States (323).  In recent years there has been an unprecedented 
development of new vaccine strategies, nevertheless, the development of a “universal 
influenza vaccine” or even more generally, successful vaccines against HIV, malaria and 
tuberculosis has been slow and challenging. This is, in part, because we still do not fully 
understand effector mechanisms that best protect against or eliminate these pathogens, 
particularly in humans (324,325). Neutralizing antibodies have been the cornerstone of 
influenza vaccine efforts for decades. Only recently have we begun to understand the 
importance of T cell immunity in generating long-lasting, cross-reactive immunity to 
influenza (68,78,81,263). Understandably, there are still a number of unanswered 
questions. For instance: what effector functions (the ability to make cytokines, 
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chemokines or cytotoxic molecules) should antigen-specific CD4 and CD8 T cells 
express to mediate optimum protection? What state of differentiation (effectors, central 
memory or effector memory) should they be in at the time of infection? How many of the 
proper type of cell is required to mediate optimum immunity? Which epitope(s) should 
the T cell and B cell responses be directed against to ensure maximum effectiveness 
against different strains? What type of formulation (live, vectored, inactivated, etc.) and 
by what route (intranasal, intramuscular, intradermal, etc.) should the vaccine be 
administered to maximally stimulate this protective response?  Are there immunological 
changes that occur soon after vaccination that can predict the development of protective 
immunity so as to facilitate the early identification of non-responders?  
Some of the above mentioned questions regarding the development of adaptive 
immune responses have been described in animal models, as briefly outlined in section 
1.2. However, despite their similarities, differences in the immune system between mice 
and humans makes the direct translation of these findings in mice to human disease 
settings challenging and time-consuming. Ethical and practical considerations limit our 
ability to perform similar studies in humans. However, vaccination represents a unique 
system that allows us do this. Obtaining blood samples at various time points post-
vaccination allows us to study the exact kinetics of innate and adaptive responses in 
humans and yet this is an opportunity that has been largely unexploited. As a part of this 
dissertation, we used seasonal influenza vaccines as a model to gain insight into 
adaptive immune mechanisms (Chapters 2 and 3).  
In chapter 2, I described the serum antibody response to seasonal TIV and LAIV. As 
has been previously been shown, we too observed robust increases in strain-specific 
serum antibody titers following parenteral vaccination with TIV. Studies in mice suggest 
that the development of primary and memory B cell responses requires a highly 
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coordinated interaction between cognate B cells and specialized follicular helper T cell 
(TFH) in germinal centers (67). In addition to providing cell associated signals, TFH cells 
secrete a variety of cytokines including IL-4, IFN-γ and IL-21 which are thought to be 
crucial to class switching and antibody production. While such molecular events are 
readily discernible in mouse models, they are near impossible to characterize in 
humans. In this study, we measured cytokines in the serum as possible biomarkers of 
such immunological events (Chapter 2). At the peak of the antibody response (day 14 
post-vaccination), we were able to detect significant changes in two important pro-
inflammatory cytokines IL-8 and TNF-α.  Measurement of serum cytokines is relatively 
easy, cost effective and can be useful biomarkers of “vaccine take” or even adverse 
reactions. The data presented in this dissertation serve as proof of principle that serum 
cytokine changes following vaccination can be readily detected in individuals. Future 
studies aimed at identifying early changes in serum cytokines that correlate with or 
predict later immunogenicity (antibody production, etc) and/or protection after 
vaccination can help in the early identification of non-responders, which is of great 
interest from a public health standpoint.  
The lack of understanding of T cell immunity in humans has, at least in part, been 
due to the lack of suitable laboratory techniques to reliably and consistently enumerate 
antigen-specific T cells. The added variability in their functional capacity to make effector 
molecules as well as their surface phenotype has compounded the complexity of T cell 
measurements. In chapter 3, we describe a novel flow cytometry-based platform for the 
functional and phenotypic characterization of antigen-specific T cells. Unlike soluble 
assays, the batch lyophilization process ensures consistency of reagents across multiple 
days and possibly even laboratories thereby minimizing day-day variability (225). We 
believe that this study may be an important step in the generation of standardized 
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reagents for the large-scale assessment of cellular immunity against not only influenza 
but also other agents.  
The limited efficacy of the seasonal vaccines in various settings (as outlined in 
section 1.3.2) and the current difficulty in generating successful new vaccines 
emphasizes the need to base future vaccine design strategies on an in-depth 
understanding of effector responses that are most beneficial for protective immunity and 
an understanding of how best to stimulate such responses (325). As the landscape of 
influenza vaccines evolves over the next few years, the development of high-throughput 
technologies and systems biology efforts that allow for the rapid and in-depth 
measurement of such responses is likely to accelerate the pace of vaccine development 
in the future (324,326). We believe the work described in this thesis takes an important 
step in that direction. We have utilized and developed innovative technologies to more 
comprehensively evaluate the humoral and cellular immune response to seasonal 
influenza vaccines. We have described our unexpected finding of serum cytokines as 
potential biomarkers of influenza vaccine induced immunity as well as the previously 
unappreciated impact of vaccination on cellular immune responses. However, several 
unanswered questions remain. Do the changes in immune markers we observed 
correlate with protection from infection/ severe disease? Will measurements of cytokines 
or antibodies in nasal wash or bronchial lavage samples be more indicative of 
immunological changes following LAIV? Can such changes be used to predict adverse 
events following vaccination?  
While the focus of the work presented here has been on adaptive immunity, in recent 
years, there has been an increased appreciation of the key role the innate immune 
system plays in sensing pathogens/vaccines/adjuvants and shaping the magnitude of 
the adaptive immune response (327). Several phenotypically distinct subsets of 
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immature and mature dendritic cells have been identified in both mice and human blood 
(reviewed in (328)). These subsets are thought to differ in their microenvironmental 
localization, TLR expression and function, although there is also evidence of some 
degree of plasticity between them. As we gain more insight to the kind of immune 
responses that are most effective in controlling specific pathogens, understanding how 
to manipulate innate immune responses using different adjuvants and/or delivery routes 
so as to generate the appropriate adaptive immune response and long-lived memory is 
key. 
In the final chapter of this thesis (Chapter 4) we sought to understand mechanisms 
that govern the development of pulmonary pathology during lethal influenza infection in 
vivo. In humans, severe disease caused by influenza is thought to be, in part, mediated 
by excessive inflammation resulting in severe pulmonary immunopathology (89). Due to 
poor disease outcomes in patients, particularly in young children and older adults (>65 
years of age), there has been a lot of interest in developing adjunct immunomodulatory 
therapies than can be used in combination with anti-virals. However, exact mechanisms 
that contribute to uncontrolled inflammation are not clear. IL-10 is a potent anti-
inflammatory cytokine that is known to play a key role in mediating immune homeostasis 
in numerous infectious and autoimmune diseases. Therefore, in chapter 4, we explored 
the role of IL-10 in controlling pulmonary immunopathology.  
Influenza virus pneumonia often occurs with or is followed by secondary bacterial 
pneumonia. In fact, approximately 96% of all deaths during the 1918 pandemic were 
likely due to secondary bacterial infections (113). Interestingly, IL-10 expression during 
influenza infection has been linked with increased susceptibility to secondary bacterial 
infections (329). In this study, we found that IL-10 regulated the expression of pulmonary 
IL-22. In addition to contributing to tissue repair, IL-22 has also been shown to play an 
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important role in controlling bacterial load by up-regulating the expression of 
antimicrobial proteins in pulmonary epithelial cells (330). It will therefore be interesting to 
utilize the Il10-/-Il22-/- generated in this study to determine if increased expression of IL-22 
in Il10-/- has an impact on secondary bacterial infection outcomes. 
The translation of findings in animal models to human disease represents a major 
challenge in identifying targets for intervention. Several recent studies have shown an 
association between IL-10 expression in serum and disease severity during influenza 
infections in humans, lending support to our findings (331,332). However, these studies 
do not reveal the cellular source of human IL-10 nor its function in vivo. A novel 
approach taken by Ranatunga, et al. utilizes BAC transgenic animals that carry the gene 
of interest along with most if not all the regulatory elements required for cell-type specific 
expression of the gene in vivo (Ranatunga, et al. PNAS). In future studies, it will be of 
interest to use this approach to gain insight into the role of human IL-10 during severe 
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candidate) 
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public 
Health, MD 
Mentor: Jay Bream, Ph.D. 
Principle responsibilities: Conduct independent graduate level research 
 Characterized the immune response to seasonal live attenuated (LAIV) and 
inactivated (TIV) influenza vaccines in a human cohort to identify potential correlates 
of protection against pandemic influenza 
o Developed a high-throughput, 10 color flow cytometry assay to perform functional 
and phenotypic characterization of influenza-specific T cells 
o Evaluated the impact of seasonal vaccination on cross-reactive antibody 
responses 
o Profiled serum cytokines as innovative biomarkers of antibody responses and 
adverse reactions 
 Demonstrated an unexpected pathogenic role for IL-10 in influenza induced 
pulmonary injury  
o Developed a mouse model of lethal influenza infection  
o Generated and maintained 6 transgenic and conditional gene knock out mouse 
lines 
o Quantified pulmonary inflammation by cytokine expression profiling, flow 
cytometric quantification of infiltrating leukocyte populations, histopathological 
examination of pulmonary tissue and viral load measurement 
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 Collaborated extensively on other laboratory projects leading to 2 co-author 
publications 
o Assisted in defining methylation patterns of the mouse and human IL10 genes 
during CD4+ T cell activation.  
o Assisted in characterizing the in vivo role of CD4+ T cell-derived human IL-10 in 
mediating protection from colitis utilizing a novel transgenic hIL10BAC mouse 
model  
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Multiparameter flow cytometry 
 Extensive experience with multicolor flow cytometry (10 colors) 
 Antibody panel design, assay development and optimization for phenotypic and 
functional characterization of antigen specific T cells 
 Flow cytometry data acquisition using BD LSRII and BD FACSCalibur and data 
analysis using BD FACSDiva and FlowJo (Tree Star) 
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 RNA and DNA extraction, cDNA synthesis, standard PCR and real-time PCR using 
SYBR green and TaqMan assays 
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 ELISA and multiplex cytokine analysis from cell culture supernatant, mouse tissue 
and mouse and human sera using BD CBA, FlowCytomix (eBioscience) and Meso 
Scale Discovery (MSD)  
 Immunohistochemistry and TUNEL staining 
Cell culture 
 Human PBMC isolation and antigen specific stimulation using overlapping peptide 
pools and live and inactivated viruses for use in flow cytometry assays 
 Aseptic cell culture techniques 
 Propagation and in vitro stimulation of the following cell lines: Madin-Darby Canine 
Kidney (MDCK) epithelial cells, RAW 264.7 mouse monocyte/macrophage cell line, 
L929 mouse fibroblasts and A549 human alveolar epithelial cells 
 Generation of mouse bone marrow derived macrophages and dendritic cells 
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 In vivo infection of mice (influenza)  
 Intranasal, intramuscular, intratracheal and intraperitoneal delivery in mice 
 Isolating mouse lungs, spleens, bronchoalveolar lavage fluid (BALF), intraepithelial 
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mesenteric lymph nodes  
 Processing mouse tissue for histological examination, cytokine/chemokine 
quantification, flow cytometric examination of leukocyte populations, Fluorescence 
Activated Cell Sorting (FACS) and/or gene expression by real-time  
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 Titration of virus from cell culture supernatant and mouse lungs using plaque 
assay, real-time PCR, standard hemagglutination assay and 50% Tissue Culture 
Infective Dose (TCID50) 
 Influenza specific antibody titration using hemagglutination inhibition assay 
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